<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Recombinant growth hormone therapy for cystic fibrosis in children and young adults - Thaker, V - 2021 | Cochrane Library</title> <meta content="Recombinant growth hormone therapy for cystic fibrosis in children and young adults - Thaker, V - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008901.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Recombinant growth hormone therapy for cystic fibrosis in children and young adults - Thaker, V - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008901.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008901.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Recombinant growth hormone therapy for cystic fibrosis in children and young adults" name="citation_title"/> <meta content="Vidhu Thaker" name="citation_author"/> <meta content="Columbia University Medical Center" name="citation_author_institution"/> <meta content="vvt2114@cumc.columbia.edu" name="citation_author_email"/> <meta content="Ben Carter" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Melissa Putman" name="citation_author"/> <meta content=" Institute of Psychiatry, Psychology &amp; Neuroscience" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD008901.pub5" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/08/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008901.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008901.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008901.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Cystic Fibrosis [complications, drug therapy]; *Diabetes Mellitus; Growth Hormone; *Human Growth Hormone; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008901.pub5&amp;doi=10.1002/14651858.CD008901.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="sogqpCtr";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008901\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008901\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ko","ms","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008901.pub5",title:"Recombinant growth hormone therapy for cystic fibrosis in children and young adults",firstPublishedDate:"Aug 23, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008901.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008901.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008901.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008901.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008901.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008901.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008901.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008901.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008901.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008901.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1699 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008901.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-sec-0184"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-sec-0173"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/appendices#CD008901-sec-0189"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/table_n/CD008901StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/table_n/CD008901StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Recombinant growth hormone therapy for cystic fibrosis in children and young adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/information#CD008901-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Vidhu Thaker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/information#CD008901-cr-0005">Ben Carter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008901.pub5/information#CD008901-cr-0006">Melissa Putman</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/information/en#CD008901-sec-0200">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 August 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008901.pub5">https://doi.org/10.1002/14651858.CD008901.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008901-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008901-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008901-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008901-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008901-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008901-abs-0006">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008901-abs-0001" lang="en"> <section id="CD008901-sec-0001"> <h3 class="title" id="CD008901-sec-0001">Background</h3> <p>Cystic fibrosis (CF) is an inherited condition causing disease most noticeably in the lungs, digestive tract and pancreas. People with CF often have malnutrition and growth delay. Adequate nutritional supplementation does not improve growth optimally and hence an anabolic agent, recombinant human growth hormone (rhGH), has been proposed as a potential intervention. This is an update of a previously published review. </p> </section> <section id="CD008901-sec-0002"> <h3 class="title" id="CD008901-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of rhGH therapy in improving lung function, quality of life and clinical status of children and young adults with CF. </p> </section> <section id="CD008901-sec-0003"> <h3 class="title" id="CD008901-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Date of latest search: 12 January 2021. </p> <p>We also searched ongoing trials registers:</p> <p>clinicaltrials.gov from the United States ‐ date of latest search 19 Jun 2021;<br/>WHO International Clinical Trials Registry Platform (ICTRP) ‐ date of latest search 05 March 2018 (not available in 2021).  </p> <p>We conducted a search of relevant endocrine journals and proceedings of the Endocrinology Society meetings using Web of Science, Scopus and Proceedings First. Date of latest search: 21 Jun 2021.  </p> </section> <section id="CD008901-sec-0004"> <h3 class="title" id="CD008901-sec-0004">Selection criteria</h3> <p>Randomised and quasi‐randomised controlled trials of all preparations of rhGH compared to either no treatment, or placebo, or each other at any dose (high‐dose and low‐dose) or route and for any duration, in children or young adults (aged up to 25 years) diagnosed with CF (by sweat test or genetic testing). </p> </section> <section id="CD008901-sec-0005"> <h3 class="title" id="CD008901-sec-0005">Data collection and analysis</h3> <p>Two authors independently screened papers, extracted trial details and assessed their risk of bias. We assessed the quality of the evidence using the GRADE system. </p> </section> <section id="CD008901-sec-0006"> <h3 class="title" id="CD008901-sec-0006">Main results</h3> <p>We included eight trials (291 participants, aged between five and 23 years) in the current version of the review. Seven trials compared standard‐dose rhGH (approximately 0.3 mg/kg/week) to no treatment and one three‐arm trial (63 participants) compared placebo, standard‐dose rhGH (0.3 mg/kg/week) and high‐dose rhGH (0.5 mg/kg/week). Six trials lasted for one year and two trials for six months. We found that rhGH treatment may improve some of the pulmonary function outcomes, but there was no difference between standard and high‐dose levels (low‐certainty evidence, limited by inconsistency across the trials, small number of participants and short duration of therapy). The trials show evidence of improvement in the anthropometric parameters (height, weight and lean body mass) with rhGH therapy, again no differences between dose levels. We found improvement in height for all comparisons (very low‐ to low‐certainty evidence), but improvements in weight and lean body mass were only reported for standard‐dose rhGH versus no treatment (very low‐certainty evidence). There is some evidence indicating a change in the level of fasting blood glucose with rhGH therapy, however, it did not cross the clinical threshold for diagnosis of diabetes in the trials of short duration (low‐certainty evidence). There is low‐ to very low‐certainty evidence for improvement of pulmonary exacerbations with no further significant adverse effects, but this is limited by the short duration of trials and the small number of participants. One small trial provided inconsistent evidence on improvement in quality of life (very low‐certainty evidence). There is limited evidence from three trials in improvements in exercise capacity (low‐certainty evidence). None of the trials have systematically compared the expense of therapy on overall healthcare costs. </p> </section> <section id="CD008901-sec-0007"> <h3 class="title" id="CD008901-sec-0007">Authors' conclusions</h3> <p>When compared with no treatment, rhGH therapy is effective in improving the intermediate outcomes in height, weight and lean body mass. Some measures of pulmonary function showed moderate improvement, but no consistent benefit was seen across all trials. The significant change in blood glucose levels, although not causing diabetes, emphasizes the need for careful monitoring of this adverse effect with therapy in a population predisposed to CF‐related diabetes. No significant changes in quality of life, clinical status or side‐effects were observed in this review due to the small number of participants. Long‐term, well‐designed randomised controlled trials of rhGH in individuals with CF are required prior to routine clinical use of rhGH in CF. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008901-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008901-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008901-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008901-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008901-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008901-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008901-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008901-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008901-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008901-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008901-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008901-abs-0002" lang="en"> <h3>The use of recombinant growth hormone to improve growth and health in children and young adults with cystic fibrosis </h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effects of recombinant human growth hormone (rhGH) on the health of people with cystic fibrosis (CF). </p> <p><b>Background</b> </p> <p>CF is an inherited condition causing disease in the lungs, digestive system and pancreas. People with CF are often underweight and have delayed growth, which may impact their lung function. Nutritional supplements may not be enough and it has been suggested that treatment with rhGH, which improves the rate of growth and bone density, might help. Treatment with rhGH is usually given once a day via a needle under the skin. It is expensive and may affect glucose metabolism that has implications for children at risk of CF‐related diabetes. Hence, we need to critically review the risks and benefits of this treatment. This is an update of an earlier review. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 12 January 2021.</p> <p><b>Study characteristics</b> </p> <p>This review looked at using of rhGH to improve lung function, growth and quality of life for children and young adults with CF. It includes eight trials with 291 individuals with CF being selected for one treatment or the other randomly. The individuals in the trials were five to 23 years old, but most had not yet reached puberty. Six trials lasted for one year and two trials for six months. Treatment with rhGH was compared to no treatment in seven trials and to a placebo (a liquid that did not contain any growth hormone) in one trial. The trial that used a placebo compared it to two different doses of rhGH treatment. </p> <p><b>Key results</b> </p> <p>Results showed a modest improvement in height, weight and lean body mass between six and 12 months. However, there was no consistent evidence that rhGH treatment improves lung function, muscle strength, or quality of life. The trials were small and we did not find any evidence on changes in glucose metabolism or the long‐term risk of diabetes due to the treatment. Given these results, we are not able to identify any clear benefit of therapy and believe that more research from well‐designed, adequately powered clinical trials is needed. </p> <p><b>Certainty of the evidence</b> </p> <p>We did not have enough information to decide if overall the trials were biased in a way that might affect the results. All the measured outcomes were clearly reported in the trials, but the trials were small and did not have enough participants to show a difference that may not have been due to chance. We also had concerns that outcomes that were based on personal judgment, such as quality of life scores, might be affected because those taking part in seven of the trials were able to tell which group they were in. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008901-sec-0184" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008901-sec-0184"></div> <h3 class="title" id="CD008901-sec-0185">Implications for practice</h3> <section id="CD008901-sec-0185"> <p>People with cystic fibrosis (CF) are at risk of malnutrition and growth failure. Therapy with recombinant growth hormone (rhGH ‐ an anabolic agent) is being proposed to boost growth and hence improve pulmonary outcomes, even though no evidence of deficiency of growth hormone has been documented in this population. There are modest improvements in anthropometric measures (height, weight, height and weight velocity and lean body mass) documented with rhGH therapy. The question of whether this improvement translates into better pulmonary outcomes, reduction in morbidity and improved quality of life (QoL) has not been answered from the evidence available at this time due to a paucity of data. Further, the statistically significant changes noted in the fasting blood glucose, although not clinically meaningful in the short‐term trials, emphasize the need for careful monitoring of parameters of blood glucose homeostasis in a population predisposed to CF‐related diabetes. Larger trials with detailed evaluation of benefits, adverse effects and a cost‐benefit analysis are recommended prior to including rhGH therapy in the routine care of people with CF. </p> </section> <h3 class="title" id="CD008901-sec-0186">Implications for research</h3> <section id="CD008901-sec-0186"> <p>Large, multicentre, randomised, placebo‐controlled, parallel‐designed trials to investigate the use of rhGH in people with CF will add important information regarding the role of this therapy. In future trials, emphasis must be placed on reporting on hospitalisation, QoL, mortality, glucose metabolism and other adverse effects. The inclusion of these adverse outcomes and the role of rhGH therapy in preventing morbidity may be helpful in a cost‐benefit analysis of the therapy. The use of standardised outcome measures in future trials can help in making the results applicable to a larger population. Longer duration of therapy will permit evaluation of the effect of rhGH therapy on puberty, slipped capital epiphysis or tendency to malignancy in this population. As rhGH therapy is implicated in glucose metabolism, the use of the therapy in people with existing glucose abnormalities will help establish adverse effects of the therapy in those with a tendency towards cystic fibrosis‐related diabetes. Future trials should include glucose tolerance tests to study impaired glucose tolerance as haemoglobin A1c is not an accurate measure in people with CF. </p> <p>Future randomised controlled trials must be well‐designed, well‐conducted, and adequately delivered with subsequent reporting, including high‐quality descriptions of all aspects of methodology. Rigorous reporting needs to conform to the Consolidated Standards of Reporting Trials (CONSORT) statement (<a href="http://www.consort-statement.org/" target="_blank">www.consort-statement.org/</a>) which will enable appraisal and interpretation of results, and accurate judgments to be made about the risk of bias, and the overall certainty of the evidence. Although it is uncertain whether reported certainty mirrors actual trial conduct, it is noteworthy that trials with unclear methodology have been shown to produce biased estimates of treatment effects. Adherence to guidelines, such as the CONSORT statement, would help ensure complete reporting. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008901-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008901-sec-0008"></div> <div class="table" id="CD008901-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Standard rhGH compared to placebo for cystic fibrosis in children and young adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard rhGH compared with placebo for children and young adults with CF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and young adults with CF </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: standard rhGH </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard rhGH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> <p>change since baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change in FEV<sub>1</sub> % predicted since baseline in the control group was 1% (23%). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the standard rhGH group was <b>2.50% higher</b> (8.60 lower to 13.60 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences were found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC (% predicted)</b> </p> <p>change since baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change in FVC % predicted from baseline in the control group was ‐0.70% (15.1%). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC (% predicted) in the standard rhGH group was <b>3.80% higher</b><br/>(4.67 lower to 12.27 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences were found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Height velocity (cm/year)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) height velocity in the control group was 3.5 (2.3) cm/year.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean height velocity in the standard rhGH group was <b>2.1 cm/year higher</b> (0.54 lower to 3.66 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Height velocity (change in height measured in cm/year) showed significant improvement in those receiving standard rhGH; however, there was no statistically significant difference in the height z score between treatment groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight (kg)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in weight in the control group was 1.4 (1.7) kg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight in the standard rhGH group was <b>1.00 kg higher</b> (‐0.08 lower to 2.08 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences were found between the two treatment groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schnabel used standardised CF HRQoL questionnaires and reported no major differences among the treatment groups (no data available for analysis). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fasting blood glucose (mg/dL)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) fasting blood glucose level in the control group was 88.8 (13.7) mg/dL.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fasting blood glucose level in the standard rhGH group was <b>12.40 mg/dL higher</b> (3.76 higher to 21.04 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference found in favour of the standard rhGH group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of pulmonary exacerbations or hospitalisations</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 pulmonary exacerbations per 1000 participants.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 pulmonary exacerbations per 1000 participants (89 to 835).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.50<br/>(0.49 to 4.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR greater than 1 indicates an advantage for placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) in the standard rhGH group is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CF</b> : cystic fibrosis;<b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume at one second; <b>FVC:</b> forced vital capacity; <b>HRQoL</b> : health‐related quality of life; <b>N/A</b> : not applicable; <b>QoL</b> : quality of life; <b>rhGH</b> : recombinant growth hormone; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to unclear risk of bias due to lack of detail on generation of allocation sequence, allocation concealment, incomplete outcome data and support from a pharmaceutical company. </p> <p>2. Downgraded due to small sample size and wide CIs.</p> <p>3. Downgraded due to lack of data for analysis.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008901-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Standard rhGH compared to no treatment for cystic fibrosis in children and young adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard rhGH compared with no treatment for children and young adults with CF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and young adults with CF </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> standard rhGH </p> <p><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard rhGH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub>(% predicted)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the control group was ‐0.4 (4.1). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted) in the intervention group was <b>0.29 higher</b> (0.62 lower to 1.19 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference between treatment groups. The change in FEV<sub>1</sub>`(L) was reported by 2 trials (n = 75) and showed a significantly greater increase in the standard rhGH group, SMD 0.74 (95% CI 0.26 to 1.22). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FVC (% predicted)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change in FVC % predicted in the control group was 0.4 (2.5) (‐0.1 to 0.4). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the intervention group was <b>1.00 higher</b> (0.03 higher to 1.96 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference found in favour of the standard rhGH group.</p> <p>The change in FVC (L) was reported by 2 trials (n = 75) and showed a significantly greater increase in the standard rhGH group, SMD 1.61 (95% CI 0.17 to 3.06). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Height velocity (cm/year)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (range) height velocity in the control group was 4.47 (3.71 to 5.3) cm/year.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean height in the intervention group was <b>3.53 cm/year higher</b> (2.77 higher to 4.30 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 participants</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference found in favour of the standard rhGH group.</p> <p>There was a similar result in favour of the rhGH treatment group in height z score measured at the end of the trial, MD 0.58 (95% CI 0.36 to 0.80). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight (kg)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (range) change in weight from baseline in the control group was 1.75 kg (0.7 to 2.8). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight in the intervention group was <b>1.00 kg higher</b> (0.32 lower to 1.68 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A separate study found no statistically significant difference between the two groups in change from baseline (kg) at six months. </p> <p>In relation to weight velocity, results were consistently significantly higher in the rhGH group at 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in HRQoL score in the control group was 0.3 (0.8).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in HRQoL score in the intervention group was <b>0.10 higher</b> (0.32 lower to 0.52 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups; however, the same trial reported a significant difference in Body Image Score favouring rhGH. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fasting blood glucose (mg/dL)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (range) fasting blood glucose in the control group was 93.33 mg/dL (88.90 mg/dL to 101.00 mg/dL). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fasting blood glucose in the intervention group was <b>3.2 mg/dL higher</b> (6.09 mg/dL lower to 12.49 mg/dL higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 participants</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between the two groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of pulmonary exacerbations or hospitalisations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (range) number of hospitalisations in the control group was 2.70 (2.2 to 3.0). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of hospitalisations in the intervention group was <b>1.34 lower</b> (1.75 lower to 0.93 lower). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 participants</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference found in favour of the standard rhGH group.</p> <p>The episodes of hospitalisations were reported as mean and SD between the 2 groups in these studies. The total number of hospitalisations in each group are not available to calculate RR. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CF</b> : cystic fibrosis;<b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume at 1 second; <b>FVC:</b> forced vital capacity; <b>HRQoL</b> : health‐related quality of life; <b>N/A</b> : not applicable; <b>QoL</b> : quality of life; <b>rhGH</b> : recombinant growth hormone; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to unclear risk of bias for generation of allocation sequence, allocation concealment and selective reporting </p> <p>2. Downgraded due to high risk of bias for blinding or incomplete outcome data or support from a pharmaceutical company (or combination of these) . </p> <p>3. Downgraded due to small sample size and wide CIs.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008901-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High‐dose rhGH compared to placebo for children and young adults with cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High‐dose rhGH compared to placebo for children and young adults with CF</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : children and young adults with CF<br/><b>Setting</b> : outpatient<br/><b>Intervention</b> : high‐dose rhGH<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>High‐dose rhGH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in FEV<sub>1</sub> % predicted in the control group was 1.0 (23.0)% predicted. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in FEV<sub>1</sub> % predicted in the intervention group was <b>3.30% higher</b> (8.16% lower to 14.76% higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC (% predicted)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in FVC % predicted in the control group was ‐0.70 (15.10) % predicted. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in FVC % predicted in the intervention group was <b>6.70% higher</b> (1.41% lower to 14.81% higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Height velocity (cm/year)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) height velocity in the control group was 3.5 (2.3) cm/year.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean height velocity in the intervention group was <b>3.30 cm/year higher</b> (1.17 higher to 5.43 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference found in favour of the standard rhGH group.</p> <p>A similarly significant result was also seen in the height z score at the end of the study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight (kg)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change in weight from baseline in the control group was 1.4 (1.7) kg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight in the intervention group was <b>0.80 kg higher</b> (0.44 lower to 2.04 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schnabel reported QoL using standardised CF HRQoL questionnaires, but did not provide data we could enter into the analysis; the published paper reported no major differences between the treatment groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fasting blood glucose (mg/dL)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) fasting blood glucose in the control group was 88.8 (13.7) mg/dL.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fasting blood glucose in the intervention group was <b>8.00 mg/dL higher</b> (0.30 mg/dL lower to 16.3 mg/dL higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of pulmonary exacerbations or hospitalisations</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 pulmonary exacerbations per 1,000 participants.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 pulmonary exacerbations per 1,000 participants (120 to 1021).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.92 (0.66 to 5.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR over 1 indicates an advantage for placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CF</b> : cystic fibrosis; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume at 1 second; <b>FVC:</b> forced vital capacity; <b>HRQoL</b> : health‐related quality of life; <b>N/A</b> : not applicable; <b>QoL</b> : quality of life; <b>rhGH</b> : recombinant growth hormone; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to unclear risk of bias due to lack of detail on generation of allocation sequence, allocation concealment, incomplete outcome data and support from a pharmaceutical company. </p> <p>2. Downgraded due to small sample size and wide CIs.</p> <p>3. Downgraded due to lack of data for analysis.</p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008901-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">High‐dose rhGH compared to standard‐dose rhGH for children and young adults with cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High‐dose rhGH compared to standard dose rhGH for children and young adults with CF</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and young adults with CF<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> high‐dose rhGH<br/><b>Comparison:</b> standard‐dose rhGH </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard‐dose rhGH</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>High‐dose rhGH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) absolute change from baseline in FEV<sub>1</sub> % predicted in the standard‐dose group was 5.60 (2.90)% predicted. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean absolute change from baseline in FEV<sub>1</sub> % predicted in the high‐dose group was <b>1.20% higher</b> (1.04% lower to 3.44% higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups. This was also true for FEV<sub>1</sub> z score. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC (% predicted)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) absolute change from baseline in FVC % predicted in the standard‐dose group was ‐0.70 (15.1) % predicted. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean absolute change from baseline in FVC % predicted in the high‐dose group was <b>6.70% higher</b> (1.29% lower to 14.69% higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Height velocity (cm/year)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in height velocity in the standard‐dose group was 5.6 (2.9) cm/year. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in height velocity in the high‐dose group was <b>1.20 cm/year higher</b> (1.04 lower to 3.44 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups. Also no difference between groups in height velocity z score. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight (kg)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in weight in the standard‐dose group was 2.4 (1.9) kg. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in weight in the high‐dose group was <b>0.2 kg lower</b> (1.48 kg lower to 1.08 kg higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fasting blood glucose (mg/dL)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) fasting blood glucose level in the standard‐dose group was 101.20 (15.2) mg/dL. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fasting blood glucose level in the high‐dose group was <b>4.40 mg/dL lower</b> (13.05 mg/dL lower to 4.25 mg/dL higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of pulmonary exacerbations or hospitalisations</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 pulmonary exacerbations per 1000 participants.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 pulmonary exacerbations per 1000 participants (142 to 868).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.28<br/>(0.52 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR greater than 1 indicates an advantage for standard rhGH.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CF</b> : cystic fibrosis; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume at 1 second; <b>FVC:</b> forced vital capacity; <b>HRQoL</b> : health‐related quality of life; <b>N/A</b> : not applicable; <b>QoL</b> : quality of life; <b>rhGH</b> : recombinant growth hormone; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to unclear risk of bias for generation of allocation sequence, concealment of allocation, lack of blinding of outcome assessment, incomplete outcome data and support from a pharmaceutical company. </p> <p>2. Downgraded due to small sample size.</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008901-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008901-sec-0009"></div> <section id="CD008901-sec-0010"> <h3 class="title" id="CD008901-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is the most common autosomal recessive genetic disease in individuals of European ancestry. With the current use of newborn screening, CF is estimated to affect 1 in 3000 to 1 in 6000 births (<a href="./references#CD008901-bbs2-0038" title="De BoeckK . Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatrica2020;109(5):893-9.">De Boeck 2020</a>; <a href="./references#CD008901-bbs2-0063" title="ScotetV , GutierrezH , FarrellPM . Newborn screening for CF across the globe - where is it worthwhile?International Journal of Neonatal Screening2020;6(1):18.">Scotet 2020</a> ). A genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene results in thickened secretions across cells causing a spectrum of clinical symptoms dominated by chronic lung disease and exocrine pancreatic insufficiency. </p> <p>Inadequate gastrointestinal function results in the malabsorption of fat, essential vitamins and fatty acids. Long‐standing lung disease increases caloric requirements compounded by a loss of appetite due to the disease, medications and the psychological stress of chronic disease (<a href="./references#CD008901-bbs2-0037" title="De BoeckK , VermeulenF , DupontL . The diagnosis of cystic fibrosis. Presse Medicale2017;46(6 Pt 2):e97-e108.">De Boeck 2017</a>; <a href="./references#CD008901-bbs2-0042" title="GoetzD , RenCL . Review of cystic fibrosis. Pediatric Annals2019;48(4):e154-61.">Goetz 2019</a>). Malnutrition and growth failure are commonly seen in people with CF; 10.5% % of people with CF under 19 years of age are below the fifth percentile for BMI and the median height percentile remains well below normal (<a href="./references#CD008901-bbs2-0031" title="Cystic Fibrosis Foundation, Bethesda, Maryland. Cystic Fibrosis Foundation Patient Registry. www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf (accessed 06 July 2021).">CFF 2019</a>). </p> <p>In the past, a failure to thrive was one of the presenting features of CF. Approximately 40% of infants were below the fifth percentile for weight and length at diagnosis with some catch‐up growth after diagnosis (<a href="./references#CD008901-bbs2-0026" title="BarkhouseLB , FaheyJ , GillespieCT , ColeDE . Quantitating the effect of cystic fibrosis on linear growth by mathematical modelling of longitudinal growth curves. Growth, Development, and Ageing1989;53(4):185-90. [PMID: 2638347]">Barkhouse 1989</a>; <a href="./references#CD008901-bbs2-0048" title="KarlbergJ , KjellmerI , KristianssonB . Linear growth in children with cystic fibrosis. I. Birth to 8 years of age. Acta Paediatrica Scandinavica1991;80(5):508-14. [PMID: 1872173]">Karlberg 1991</a>; <a href="./references#CD008901-bbs2-0050" title="LaiHC , KosorokMR , SondelSA , ChenST , FitzSimmonsSC , GreenCG , et al. Growth status in children with cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: evaluation of various criteria used to identify malnutrition. Journal of Pediatrics1998;132(3 Pt 1):478-85. [PMID: 9544905]">Lai 1998</a>; <a href="./references#CD008901-bbs2-0057" title="MorisonS , DodgeJA , ColeTJ , LewisPA , ColesEC , GeddesD , et al. Height and weight in cystic fibrosis: a cross sectional study. UK Cystic Fibrosis Survey Management Committee. Archives of Disease in Childhood1997;77(6):497-500. [PMID: 9496182]">Morison 1997</a>). In the USA, since the introduction of newborn screening for CF, failure to thrive is less likely to be seen, but poor growth is still a problem (<a href="./references#CD008901-bbs2-0032" title="CoffeyMJ , WhitakerV , GentinN , JunekR , ShalhoubC , NightingaleS , et al. Differences in outcomes between early and late diagnosis of cystic fibrosis in the newborn screening era. The Journal of Pediatrics2017;181:137-45.e1. [PMID: 27837951]">Coffey 2017</a>; <a href="./references#CD008901-bbs2-0053" title="LeungDH , HeltsheSL , BorowitzD , GelfondD , KlosterM , HeubiJE , et al. Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life. JAMA Pediatrics2017;171(6):546-54. [PMID: 28437538]">Leung 2017</a>). </p> <p>Height and weight influence pulmonary function in people with CF (<a href="./references#CD008901-bbs2-0055" title="MauchRM , KmitAH , MarsonFA , LevyCE , Barros-FilhoAA , RibeiroJD . Association of growth and nutritional parameters with pulmonary function in cystic fibrosis: a literature review [Associacao dos parametros de crescimento e nutricionais com funcao pulmonar na fibrose cistica: revisao da literatura.]. Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo2016;34(4):503-9. [PMID: 27181343]">Mauch 2016</a>; <a href="./references#CD008901-bbs2-0076" title="ZemelBS , JawadAF , FitzSimmonsS , StallingsVA . Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. The Journal of Pediatrics2000;137(3):374-80. [PMID: 10969263]">Zemel 2000</a>). Diagnosis by newborn screening has significantly improved the long‐term height and weight outcomes in children and adolescents with CF, but benefits on lung function are yet to be identified (<a href="./references#CD008901-bbs2-0025" title="AssaelBM , CasazzaG , IansaP , VolpiS , MilaniS . Growth and long-term lung function in cystic fibrosis: a longitudinal study of patients diagnosed by neonatal screening. Pediatric Pulmonology2009;44(3):209-15. [PMID: 19230003]">Assael 2009</a>; <a href="./references#CD008901-bbs2-0053" title="LeungDH , HeltsheSL , BorowitzD , GelfondD , KlosterM , HeubiJE , et al. Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life. JAMA Pediatrics2017;171(6):546-54. [PMID: 28437538]">Leung 2017</a>). </p> <p>After infancy, the rate of growth of children with CF follows a nearly normal pattern in the pre‐pubertal age, albeit at lower centiles (<a href="./references#CD008901-bbs2-0031" title="Cystic Fibrosis Foundation, Bethesda, Maryland. Cystic Fibrosis Foundation Patient Registry. www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf (accessed 06 July 2021).">CFF 2019</a>; <a href="./references#CD008901-bbs2-0053" title="LeungDH , HeltsheSL , BorowitzD , GelfondD , KlosterM , HeubiJE , et al. Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life. JAMA Pediatrics2017;171(6):546-54. [PMID: 28437538]">Leung 2017</a>; <a href="./references#CD008901-bbs2-0075" title="YenEH , QuintonH , BorowitzD . Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. Journal of Pediatrics2013;162(3):530-5.e1.">Yen 2013</a>). The adolescent years show more severe growth impairment associated with a delay in skeletal maturation, a delayed pubertal growth spurt, and the attainment of adult height (<a href="./references#CD008901-bbs2-0043" title="HaeuslerG , FrischH , WaldhorT , GotzM . Perspectives of  longitudinal growth in cystic fibrosis from birth to adult age. European Journal of Pediatrics1994;153(3):158-63.">Haeusler 1994</a>; <a href="./references#CD008901-bbs2-0054" title="LucidiV , AlghisiF , RaiaV , RussoB , ValmaranaL , ValmaranaR , et al. Growth assessment of paediatric patients with CF comparing different auxologic indicators: A multicentre Italian study. Journal of Pediatric Gastroenterology and Nutrition2009;49(3):335-42. [PMID: 19543116]">Lucidi 2009</a>; <a href="./references#CD008901-bbs2-0057" title="MorisonS , DodgeJA , ColeTJ , LewisPA , ColesEC , GeddesD , et al. Height and weight in cystic fibrosis: a cross sectional study. UK Cystic Fibrosis Survey Management Committee. Archives of Disease in Childhood1997;77(6):497-500. [PMID: 9496182]">Morison 1997</a>). Despite comprehensive care at specialised centres, studies show that growth in individuals with CF remains below that of controls or healthy peers (<a href="./references#CD008901-bbs2-0067" title="StettlerN , KawchakDA , BoyleLL , PropertKJ , ScanlinTF , StallingsVA , et al. Prospective evaluation of growth, nutritional status, and body composition in children with cystic fibrosis. American Journal of Clinical Nutrition2000;72(2):407-13. [PMID: 10919935]">Stettler 2000</a>; <a href="./references#CD008901-bbs2-0071" title="WiedemannB , PaulKD , SternM , WagnerTO , HircheTO . Evaluation of body mass index percentiles for assessment of malnutrition in children with cystic fibrosis. European Journal of Clinical Nutrition2007;61(6):759-68. [PMID: 17213872]">Wiedemann 2007</a>). Consequently, the height of adults with CF is reduced (<a href="./references#CD008901-bbs2-0030" title="ByardPJ . The adolescent growth spurt in children with cystic fibrosis. Annals of Human Biology1994;21(3):229-40.">Byard 1994</a>; <a href="./references#CD008901-bbs2-0031" title="Cystic Fibrosis Foundation, Bethesda, Maryland. Cystic Fibrosis Foundation Patient Registry. www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf (accessed 06 July 2021).">CFF 2019</a>; <a href="./references#CD008901-bbs2-0054" title="LucidiV , AlghisiF , RaiaV , RussoB , ValmaranaL , ValmaranaR , et al. Growth assessment of paediatric patients with CF comparing different auxologic indicators: A multicentre Italian study. Journal of Pediatric Gastroenterology and Nutrition2009;49(3):335-42. [PMID: 19543116]">Lucidi 2009</a>). </p> <p>Malnutrition and short stature have been shown to contribute to an individual's poor clinical outcome (<a href="./references#CD008901-bbs2-0033" title="CoreyM , McLaughlinFJ , WilliamsM , LevisonH . A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of Clinical Epidemiology1988;41(6):583-91. [PMID: 3260274]">Corey 1988</a>; <a href="./references#CD008901-bbs2-0042" title="GoetzD , RenCL . Review of cystic fibrosis. Pediatric Annals2019;48(4):e154-61.">Goetz 2019</a>; <a href="./references#CD008901-bbs2-0052" title="LeTN , AnabtawiA , PutmanMS , TangprichaV , StalveyMS . Growth failure and treatment in cystic fibrosis. Journal of Cystic Fibrosis2019;18 Suppl 2:S82-7.">Le 2019</a>). While the nutritional care of people with CF has improved significantly,  children with CF remain shorter than their peers and fail to reach their genetic potential (<a href="./references#CD008901-bbs2-0077" title="Zysman-ColmanZN , KilbergMJ , HarrisonVS , ChesiA , GrantSF , MitchellJ , et al. Genetic potential and height velocity during childhood and adolescence do not fully account for shorter stature in cystic fibrosis. Pediatric Research2021;89(3):653-659.">Zysman‐Colman 2021</a>). Height is a significant prognostic factor for CF and poor growth adversely impacts lung function and overall health status (<a href="./references#CD008901-bbs2-0027" title="BekerLT , Russek-CohenE , FinkRJ . Stature as a prognostic factor in cystic fibrosis survival. Journal of the American Dietetic Association2001;101(4):438-42.">Beker 2001</a>; <a href="./references#CD008901-bbs2-0056" title="McColleySA , SchechterMS , MorganWJ , PastaDJ , CraibML , KonstanMW . Risk factors for mortality before age 18 years in cystic fibrosis. Pediatric Pulmonology2017;52(7):909-15.">McColley 2017</a>; <a href="./references#CD008901-bbs2-0075" title="YenEH , QuintonH , BorowitzD . Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. Journal of Pediatrics2013;162(3):530-5.e1.">Yen 2013</a>). Prospective studies have also shown that aggressive nutritional intervention may positively affect pulmonary function (<a href="./references#CD008901-bbs2-0049" title="KonstanMW , ButlerSM , WohlME , StoddardM , MatousekR , WagenerJS , et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. Journal of Pediatrics2003;142(6):624-30.">Konstan 2003</a>; <a href="./references#CD008901-bbs2-0065" title="SharmaR , FloreaVG , BolgerAP , DoehnerW , FloreaND , CoatsAJ , et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax2001;56(10):746-50.">Sharma 2001</a>). It is possible that improved growth may allow more lung mass and better lung function, which could be important, independent of the issue of improving weight gain. However, despite adherence to updated nutritional guidelines, there are still people with CF who cannot meet their energy needs or maintain the benefits of nutritional interventions (<a href="./references#CD008901-bbs2-0035" title="DalzellAM , ShepherdRW , DeanB , CleghornGJ , HoltTL , FrancisPJ . Nutritional rehabilitation in cystic fibrosis: a 5 year follow-up study. Journal of Pediatric Gastroenterology and Nutrition1992;15(2):141-5.">Dalzell 1992</a>; <a href="./references#CD008901-bbs2-0067" title="StettlerN , KawchakDA , BoyleLL , PropertKJ , ScanlinTF , StallingsVA , et al. Prospective evaluation of growth, nutritional status, and body composition in children with cystic fibrosis. American Journal of Clinical Nutrition2000;72(2):407-13. [PMID: 10919935]">Stettler 2000</a>) and who are at risk of nutritional failure and deterioration of pulmonary function.  </p> <p>Individuals with CF have been consistently shown to have low levels of GH effector proteins (insulin‐like growth factor ‐1 (IGF‐1) and binding proteins (IGFBP‐3) which correlate with height and body mass index (BMI) (<a href="./references#CD008901-bbs2-0028" title="BoguszewskiMC , KamoiTO , Bento RadominskiR , BoguszewskiCL , RosbergS , FilhoNA , et al. Insulin-like growth factor-1, leptin, body composition, and clinical status interactions in children with cystic fibrosis. Hormone Research2007;67(5):250-6.">Boguszewski 2007</a>; <a href="./references#CD008901-bbs2-0062" title="RoganMP , ReznikovLR , PezzuloAA , GansemerND , SamuelM , PratherRS , et al. Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proceedings of the National Academy of Sciences USA2010;107(47):20571-5.">Rogan 2010</a>).  Whether this is due to decreased GH production,  relative GH insensitivity, or CFTR dysfunction itself is not clearly defined (<a href="./references#CD008901-bbs2-0052" title="LeTN , AnabtawiA , PutmanMS , TangprichaV , StalveyMS . Growth failure and treatment in cystic fibrosis. Journal of Cystic Fibrosis2019;18 Suppl 2:S82-7.">Le 2019</a>; <a href="./references#CD008901-bbs2-0051" title="LaursenEM , LanngS , RasmussenMH , KochC , SkakkebaekNE , MullerJ . Normal spontaneous and stimulated GH levels despite decreased IGF-I concentrations in cystic fibrosis patients. European Journal of Endocrinology1999;140(4):315-21. [PMID: 10097250]">Laursen 1999</a>; <a href="./references#CD008901-bbs2-0069" title="TaylorAM , BushA , ThomsonA , OadesPJ , MarchantJL , Bruce-MorganC , et al. Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis. Archives of Disease in Childhood1997;76(4):304-9. [PMID: 9166020]">Taylor 1997</a>). In addition, the chronic inflammation in CF results in the production of inflammatory chemicals like body interleukins (IL‐1, IL‐6) and tumour necrosis factor (TNF‐alpha), which have also been shown to reduce levels of IGF‐1 (<a href="./references#CD008901-bbs2-0036" title="De BenedettiF , AlonziT , MorettaA , LazzaroD , CostaP , PoliV , et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. Journal of Clinical Investigation1997;99(4):643-50. [PMID: 9045866]">De Benedetti 1997</a>; <a href="./references#CD008901-bbs2-0074" title="WongSC , DobieR , AltowatiMA , WertherGA , FarquharsonC , AhmedSF . Growth and the growth hormone insulin like growth factor 1 axis in children with chronic inflammation: current evidence, gaps in knowledge, and future directions. Endocrine Reviews2016;37(1):62-110.">Wong 2016</a>). There is strong evidence that low IGF‐1 levels result in loss of lean body mass and respiratory muscle wasting which ultimately results in the deterioration of lung function and increasing morbidity (<a href="./references#CD008901-bbs2-0064" title="Sermet-GaudelusI , SouberbielleJC , AzharI , RuizJC , MagnineP , ColombV , et al. Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients. Archives of Disease in Childhood2003;88(11):956-61. [PMID: 14612353]">Sermet‐Gaudelus 2003</a>). </p> </section> <section id="CD008901-sec-0011"> <h3 class="title" id="CD008901-sec-0011">Description of the intervention</h3> <p>GH acts to mediate growth and metabolic functions in the body. It is released from the pituitary gland in a pulsatile manner throughout the day. At night GH release peaks and stimulates the production of IGF‐1 in the liver, which is its major effector protein and also serves to control its secretion (<a href="./references#CD008901-bbs2-0072" title="MelmedS , PolonskyK , ReedLarsenP , KronenbergH . Williams Textbook of Endocrinology. 12th edition. St. Louis, Missouri, USA: Elsevier, W.B. Saunders, 2011.">Williams 2011</a>). </p> <p>Recombinant human GH (rhGH) (somatotropin) has been available since 1985 and is self‐administered at home, usually as a subcutaneous injection. The frequency of dose is generally six to seven times per week, preferably at night to mimic the body's natural rhythm. The dose of the therapy generally varies between 0.1 mg to 0.4 mg/kg/week depending on the clinical condition. </p> <p>Treatment with rhGH is expensive. According to an NHS Health Technology Assessment Programme, the costs for treating children with four of the licensed conditions (growth hormone deficiency, Prader Willi Syndrome, idiopathic short stature and Turners syndrome) in England and Wales with rhGH would be approximately GBP 180 million (<a href="./references#CD008901-bbs2-0029" title="BryantJ , CaveC , MihaylovaB , ChaseD , McIntyreL , GerardK , et al. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technology Assessment2002;6(18):1-168.">Bryant 2002</a>). For GH deficiency, the cost of therapy (in 2000) for a nine‐year‐old child for eight years would average more than GBP 50,000 and that for a 12‐year old child for five years over GBP 40,000 (<a href="./references#CD008901-bbs2-0029" title="BryantJ , CaveC , MihaylovaB , ChaseD , McIntyreL , GerardK , et al. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technology Assessment2002;6(18):1-168.">Bryant 2002</a>). This raises the question of consideration of cost‐benefit analysis for the use of therapy, especially if anticipated costs are higher, as in CF. </p> <section id="CD008901-sec-0012"> <h4 class="title">Adverse effects of the therapy</h4> <p>Besides the discomfort and local reactions caused by daily injections, mild adverse effects like headache, nausea, fever and vomiting have been noted. Overall, the incidence of adverse effects in children treated with rhGH therapy is under 3%. Adverse effects associated with rhGH therapy are intracranial hypertension (pseudotumour cerebri), moderate and severe edema, slipped capital femoral epiphysis, worsening of scoliosis, gynaecomastia and hyperglycaemia (<a href="./references#CD008901-bbs2-0073" title="WilsonTA , RoseSR , CohenP , RogolAD , BackeljauwP , BrownR , et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. Journal of Pediatrics2003;143(4):415-21. [PMID: 14571209]">Wilson 2003</a>). There have been some recent concerns that rhGH therapy may increase the tendency towards new tumour formation (<a href="./references#CD008901-bbs2-0041" title="GiovannucciE , HaimanCA , PlatzEA , HankinsonSE , PollakMN , HunterDJ . Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiology, Biomarkers and Prevention2002;11(11):1509-10.">Giovannucci 2002</a>; <a href="./references#CD008901-bbs2-0070" title="VerhelstJ , AbsR . Long-term growth hormone replacement therapy in hypopituitary adults. Drugs2002;62(16):2399-412.">Verhelst 2002</a>), although there are no current documented results with short‐ and long‐term follow‐up in children and adults. </p> <p>In trials assessing the results of rhGH therapy on glucose metabolism, a slight increase in fasting and post‐prandial insulin and blood glucose levels has been demonstrated (<a href="./references#CD008901-bbs2-0034" title="CutfieldWS , WiltonP , BennmarkerH , Albertsson-WiklandK , ChatelainP , RankeMB , et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet2000;355(9204):610-3. [PMID: 10696981]">Cutfield 2000</a>; <a href="./references#CD008901-bbs2-0047" title="JeffcoateW . Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Safety2002;25(3):199-212.">Jeffcoate 2002</a>). In pre‐pubertal children with CF at high risk for CF‐related diabetes, the long‐term safety of rhGH therapy should be an important consideration. </p> </section> </section> <section id="CD008901-sec-0013"> <h3 class="title" id="CD008901-sec-0013">How the intervention might work</h3> <p>Treatment with rhGH can accelerate linear growth in pre‐pubertal children with growth failure including those with CF (<a href="./references#CD008901-bbs2-0044" title="HardinDS . GH improves growth and clinical status in children with cystic fibrosis -- a review of published studies. European Journal of Endocrinology / European Federation of Endocrine Societies2004;151(Suppl 1):S81-5.">Hardin 2004</a>). It also modifies body composition, promoting fat‐free mass in the body. In the long term, rhGH treatment increases bone mass and bone mineral density which can be detected by dual energy X‐ray absorptiometry (DEXA) scan. </p> <p>In children with CF, rhGH increases IGF‐1 levels and improves growth velocity, lean body mass and bone density (<a href="./references#CD008901-bbs2-0014" title="HardinDS , SyJP . Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience. Journal of Pediatrics1997;131(1 Pt 2):S65-9. [PMID: 9255232]">Hardin 1997</a>; <a href="./references#CD008901-bbs2-0017" title="HusemanCA , ColomboJL , BrooksMA , SmayJR , GregerNG , SammutPH , et al. Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients. Pediatric Pulmonology1996;22(2):90-5. [PMID: 8875581]">Huseman 1996</a>). Improved linear growth can improve pulmonary function, exercise capacity, reduce infection rates and provide a better quality of life (QoL) (<a href="./references#CD008901-bbs2-0027" title="BekerLT , Russek-CohenE , FinkRJ . Stature as a prognostic factor in cystic fibrosis survival. Journal of the American Dietetic Association2001;101(4):438-42.">Beker 2001</a>; <a href="./references#CD008901-bbs2-0033" title="CoreyM , McLaughlinFJ , WilliamsM , LevisonH . A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of Clinical Epidemiology1988;41(6):583-91. [PMID: 3260274]">Corey 1988</a>). It was also noted that rhGH reduced TNF‐alpha in people with CF and reduces protein degradation (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>). </p> </section> <section id="CD008901-sec-0014"> <h3 class="title" id="CD008901-sec-0014">Why it is important to do this review</h3> <p>Therapy with rhGH has potential side effects such as impairment in glucose metabolism. Presently there is no agreement on the use of rhGH therapy in individuals with CF. A systematic review of the use of rhGH in people with CF is needed to evaluate the treatment outcomes before justifying treatment. If a systematic review of the studies reveals a benefit in pulmonary function, the QoL, and morbidity (including hospitalisations) for people with CF, this will serve as an important adjunct to their current therapy. </p> <p>This is an update of a previously published review (<a href="./references#CD008901-bbs2-0078" title="ThakerV , HaagensenAL , CarterB , FedorowiczZ , HoustonBW . Recombinant growth hormone therapy for cystic fibrosis in children and young adults. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD008901. [DOI: 10.1002/14651858.CD008901.pub2]">Thaker 2013</a>; <a href="./references#CD008901-bbs2-0079" title="ThakerV , HaagensenAL , CarterB , FedorowiczZ , HoustonBW . Recombinant growth hormone therapy for cystic fibrosis in children and young adults. Cochrane Database of Systematic Reviews2015, Issue 5. Art. No: CD008901. [DOI: 10.1002/14651858.CD008901.pub3]">Thaker 2015</a>; <a href="./references#CD008901-bbs2-0080" title="ThakerV , CarterB , PutmanM . Recombinant growth hormone therapy for cystic fibrosis in children and young adults. Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD008901. [DOI: 10.1002/14651858.CD008901.pub4]">Thaker 2018</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008901-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008901-sec-0015"></div> <p>To evaluate the effectiveness and safety of rhGH therapy in improving lung function, QoL and clinical status of children and young adults with CF. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008901-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008901-sec-0016"></div> <section id="CD008901-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008901-sec-0018"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and quasi‐RCTs.</p> </section> <section id="CD008901-sec-0019"> <h4 class="title">Types of participants</h4> <p>Participants of either sex up to the age of 25 years with a confirmed diagnosis of CF (e.g. by sweat test or molecular diagnosis) who have not received rhGH therapy in the previous six months. </p> </section> <section id="CD008901-sec-0020"> <h4 class="title">Types of interventions</h4> <p>Therapy with rhGH at any dose compared to placebo, no treatment or a different dose regimen. </p> </section> <section id="CD008901-sec-0021"> <h4 class="title">Types of outcome measures</h4> <p>We assessed the following outcomes.</p> <section id="CD008901-sec-0022"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008901-list-0001"> <li> <p>Pulmonary function tests</p> <ol id="CD008901-list-0002"> <li> <p>forced expiratory volume at one second (FEV<sub>1</sub>) (% predicted or litres) </p> </li> <li> <p>forced vital capacity (FVC) (% predicted or litres)</p> </li> <li> <p>maximal inspiratory pressure (PImax)</p> </li> <li> <p>maximal expiratory pressure (PEmax)</p> </li> </ol> </li> <li> <p>Anthropometric parameters</p> <ol id="CD008901-list-0003"> <li> <p>height (cm) and height z score or standard deviation score (SDS)</p> </li> <li> <p>height velocity</p> </li> <li> <p>weight (kg) and weight z score or SDS</p> </li> <li> <p>weight velocity</p> </li> <li> <p>lean body mass (LBM) measured by DEXA scan</p> </li> </ol> </li> <li> <p>QoL (measured by a validated tool such as the Cystic Fibrosis Questionnaire‐Revised version (CFQ‐R (<a href="./references#CD008901-bbs2-0060" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>)) and the Cystic Fibrosis Quality of Life Questionnaire (CFQoL (<a href="./references#CD008901-bbs2-0040" title="GeeL , AbbottJ , ConwayS , EtheringtonC , WebbA . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax2000;55(11):946-54.">Gee 2000</a>)) </p> </li> </ol> </p> </section> <section id="CD008901-sec-0023"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008901-list-0004"> <li> <p>Impact of rhGH therapy on blood glucose abnormality</p> <ol id="CD008901-list-0005"> <li> <p>impact on fasting insulin levels in non‐diabetic participants (by measuring insulin levels) </p> </li> <li> <p>fasting blood glucose (FBG) and post‐prandial blood glucose (PPBG) levels (haemoglobin A1c levels and oral glucose tolerance tests) </p> </li> <li> <p>change in exogenous insulin requirements and blood sugar control in diabetic participants</p> </li> </ol> </li> <li> <p>Muscular strength and exercise capacity</p> <ol id="CD008901-list-0006"> <li> <p>changes in overall muscle strength (as measured by hand grip or bicycle ergometry (post hoc change)) </p> </li> <li> <p>six‐minute walk</p> </li> </ol> </li> <li> <p>Serum insulin‐like growth factor‐1 (IGF‐1) levels and insulin‐like growth factor binding protein 3 (IGFBP‐3) levels </p> </li> <li> <p>Change in disease exacerbation</p> <ol id="CD008901-list-0007"> <li> <p>hospitalisation</p> <ol id="CD008901-list-0008"> <li> <p>frequency</p> </li> <li> <p>duration</p> </li> </ol> </li> <li> <p>need for antibiotics</p> <ol id="CD008901-list-0009"> <li> <p>oral</p> </li> <li> <p>intravenous</p> </li> </ol> </li> </ol> </li> <li> <p>Any adverse effects reported</p> <ol id="CD008901-list-0010"> <li> <p>mild, requiring no treatment (e.g. transient glucosuria, transient splenomegaly and muscular prominence) </p> </li> <li> <p>moderate, requiring treatment (e.g. benign intracranial hypertension, effects on glucose metabolism) </p> </li> <li> <p>life‐threatening or severe (requiring hospitalisation) (e.g. slipped capital epiphyses, incidence of malignant disease) </p> </li> </ol> </li> <li> <p>Cost</p> </li> </ol> </p> </section> </section> </section> <section id="CD008901-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <p>Searches were not limited by language or publication status.</p> <section id="CD008901-sec-0025"> <h4 class="title">Electronic searches</h4> <p>We identified relevant studies from the Group's Cystic Fibrosis Trials Register using the terms: treatment of growth failure AND (rhGH OR not stated). </p> <p>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of EMBASE to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cochrane Cystic Fibrosis and Genetic Disorders Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of the latest search: 12 January 2021.</p> <p>We conducted a search of relevant endocrine journals and proceedings of the Endocrinology and Pulmonary Society meetings. We used Web of Science, Scopus and Proceedings First to conduct this search. </p> <p>Date of the latest search: 19 June 2021.</p> <p>We searched the online trial registries at <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>. Date of latest search: 22 June 2021. </p> <p>We last searched the WHO International Clinical Trials Registry Platform (ICTRP) at <a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/trialsearch</a> for ongoing clinical trials on 05 March 2018. We were unable to access this database in 2021 due to the Covid‐19 pandemic. </p> <p>The search strategies for these additional electronic searches are detailed in the appendices (<a href="./appendices#CD008901-sec-0190">Appendix 1</a>). </p> </section> <section id="CD008901-sec-0026"> <h4 class="title">Searching other resources</h4> <p>The bibliographic references of identified trials were reviewed for references to additional trials. </p> </section> </section> <section id="CD008901-sec-0027"> <h3 class="title" id="CD008901-sec-0027">Data collection and analysis</h3> <section id="CD008901-sec-0028"> <h4 class="title">Selection of studies</h4> <p>Two authors (VT and BH, and from 2018, MP) independently assessed the abstracts of trials identified from the searches. We obtained full copies of all relevant and potentially relevant trials (those appearing to meet the inclusion criteria, and for which there were insufficient data in the title and abstract to make a clear decision). The two review authors (VT, BH and from 2018 MP) then independently assessed the full text papers and resolved any disagreement on the eligibility of included trials through discussion and consensus or, if necessary, through a third author (BC). We then excluded those records that did not meet the inclusion criteria and we noted the reasons for their exclusion in the '<a href="./references#CD008901-sec-0207" title="">Characteristics of excluded studies</a>' table in the review. </p> </section> <section id="CD008901-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>We entered trial details into the '<a href="./references#CD008901-sec-0206" title="">Characteristics of included studies</a>' table in the review and collected outcome data using a pre‐determined form designed for this purpose. Two authors (VT, BH and subsequently MP) independently extracted data and only included data for which there was a consensus. We resolved any disagreements by consulting with a third review author (BC). </p> <p>We extracted the following details.</p> <p> <ol id="CD008901-list-0011"> <li> <p>Trial methods</p> <ol id="CD008901-list-0012"> <li> <p>method of allocation</p> </li> <li> <p>allocation concealment</p> </li> <li> <p>masking of participants, clinicians and outcome assessors</p> </li> <li> <p>exclusion of participants after randomisation and proportion and reasons for losses at follow‐up </p> </li> </ol> </li> <li> <p>Participants</p> <ol id="CD008901-list-0013"> <li> <p>country of origin and study setting</p> </li> <li> <p>sample size</p> </li> <li> <p>age</p> </li> <li> <p>gender</p> </li> <li> <p>inclusion and exclusion criteria</p> </li> </ol> </li> <li> <p>Intervention</p> <ol id="CD008901-list-0014"> <li> <p>trial duration</p> </li> <li> <p>type</p> </li> <li> <p>concentration, dose and frequency</p> </li> <li> <p>duration of intervention in follow‐up</p> </li> </ol> </li> <li> <p>Control</p> <ol id="CD008901-list-0015"> <li> <p>type</p> </li> <li> <p>concentration, dose and frequency</p> </li> <li> <p>duration of intervention in follow‐up</p> </li> </ol> </li> <li> <p>Outcomes:</p> <ol id="CD008901-list-0016"> <li> <p>primary and secondary outcomes mentioned in the <a href="http://archie.cochrane.org/sections/documents/view?version=57287766047329531747100403052239&amp;format=REVMAN#CRIT_OUTCOMES" target="_blank">Types of outcome measures</a> section of this review </p> </li> </ol> </li> </ol> </p> <p>If stated, we recorded the sources of funding of any of the included trials.</p> <p>We used this information to help assess heterogeneity and the external validity of any included trials. We used Cochrane's Review Manager software for data organisation and analysis (<a href="./references#CD008901-bbs2-0061" title="The Cochrane CollaborationReview Manager (RevMan). Version Version 5.4. The Cochrane Collaboration, 2020.">RevMan 2020</a>). </p> </section> <section id="CD008901-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Each review author graded the selected trials using a simple contingency form and followed the domain‐based evaluation described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008901-bbs2-0045" title="HigginsJP , AltmanDG , Sterne JA on behalf of the CSMG and the CBMG , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011a</a>). The authors compared the evaluations and discussed and resolved any inconsistencies in these evaluations. </p> <p>We assessed the following domains as having either a low, unclear or high risk of bias: </p> <p> <ol id="CD008901-list-0017"> <li> <p>sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding (of participants, personnel and outcome assessors); </p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting;</p> </li> <li> <p>other bias.</p> </li> </ol> </p> <p>We categorised the risk of bias in any included trial according to the following:</p> <p> <ul id="CD008901-list-0018"> <li> <p>low risk of bias (plausible bias unlikely to seriously alter the results) if all criteria were met; </p> </li> <li> <p>unclear risk of bias (plausible bias that raises some doubt about the results) if one or more criteria were assessed as unclear; or  </p> </li> <li> <p>high risk of bias (plausible bias that seriously weakens confidence in the results) if one or more criteria were not met. </p> </li> </ul> </p> <p>We report these assessments in the table 'Risk of bias in included studies' in the review. </p> </section> <section id="CD008901-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (need for antibiotics, number of people with pulmonary exacerbations and adverse effects), we reported the results as the risk ratio (RR) with 95% confidence intervals (CI). For continuous outcomes (pulmonary function tests, nutritional parameters, QoL, blood glucose levels, muscular strength and exercise capacity, measures of serum IGF‐1 levels, cost of therapy and hospitalisation), we reported the mean relative change from baseline for each group or mean post‐intervention values and their standard deviations (SD). We used Review Manager software to analyse the data (<a href="./references#CD008901-bbs2-0061" title="The Cochrane CollaborationReview Manager (RevMan). Version Version 5.4. The Cochrane Collaboration, 2020.">RevMan 2020</a>). We reported data as the mean difference (MD) or standardised mean difference (SMD) if different units are used with 95% CIs. </p> <p>We processed data according to the intention‐to‐treat principle, using in the denominator the number of randomised participants. We assumed missing values for outcome measures to represent a poor outcome for both groups. </p> </section> <section id="CD008901-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>We did not include any cluster‐RCTs, and we reported repeated measures studies that collected multiple time points for outcomes at clinically relevant time points as discussed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008901-bbs2-0046" title="HigginsJP , DeeksJJ , Altman DG on behalf of the CSMG , editor(s). Chapter 16: Special topics in statistics. In: Higgins JP, Green S editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011b</a>). </p> <p>We have included data from the first period of cross‐over trials (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). We have excluded data from later periods of cross‐over studies as the duration of treatment effect and the disease effect are more likely to develop over different time periods and the appropriate washout period cannot be clearly defined. </p> </section> <section id="CD008901-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>We contacted primary research investigators about missing data from included and ongoing trials. We have provided a narrative synthesis of information where data were not provided. </p> </section> <section id="CD008901-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by examining the characteristics of the trials, the similarity between the types of participants, the interventions and the outcomes as specified in the criteria for included trials. We used the I² statistic to assess heterogeneity. If we found moderate levels of heterogeneity for the primary outcomes (I² greater than 50%), we would have explored reasons for heterogeneity using subgroup analysis. We considered heterogeneity to be significant when the P value was less than 0.10 (<a href="http://archie.cochrane.org/sections/documents/view?version=25752779853707313578101110131157&amp;format=REVMAN#REF-Higgins-2003" target="_blank">Higgins 2003</a>). </p> </section> <section id="CD008901-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias according to the recommendations on testing for funnel plot asymmetry (<a href="http://archie.cochrane.org/sections/documents/view?version=57287766047329531747100403052239&amp;format=REVMAN#REF-Egger-1997" target="_blank">Egger 1997</a>) and as described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008901-bbs2-0066" title="SterneJA , EggerM , Moher D on behalf of the CBMG , editor(s). Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Sterne 2011</a>); however, we were unable to do so due to a lack of data available for analysis. </p> </section> <section id="CD008901-sec-0036"> <h4 class="title">Data synthesis</h4> <p>For the synthesis and meta‐analysis of any quantitative data we used the random‐effects model. We did not consider it appropriate to combine data for any outcome due to the differences in participant characteristics where trial data were reported at the same time points. </p> <p>We sought statistical support from the Cochrane Cystic Fibrosis and Genetic Disorders Group. Two review authors (VT, BC) analysed data reported in the included studies and relevant to the primary and secondary outcomes of this review using the Review Manager software (<a href="./references#CD008901-bbs2-0061" title="The Cochrane CollaborationReview Manager (RevMan). Version Version 5.4. The Cochrane Collaboration, 2020.">RevMan 2020</a>). We report results as suggested in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008901-bbs2-0039" title="DeeksJJ , HigginsJP , Altman DG on behalf of the CSMG , editor(s). Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Deeks 2011</a>). </p> </section> <section id="CD008901-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We have not performed any subgroup analyses to date due to the small amount of data, the inability to obtain raw data and the absence of heterogeneity. In future updates, if we identify further trials and are able to combine results that then show heterogeneity (I² greater than 50%), we will undertake subgroup analyses for the following groups: </p> <p> <ol id="CD008901-list-0019"> <li> <p>Tanner stage of puberty (<a href="./references#CD008901-bbs2-0068" title="TannerJM . Growth at Adolescence. Springfield, IL: Charles C Thomas, 1962.">Tanner 1962</a>); </p> </li> <li> <p>gender;</p> </li> <li> <p>baseline nutritional or anthropometric status;</p> </li> <li> <p>lung function (FEV<sub>1</sub> &lt; 50%, 50% to 80% and &gt; 80%). </p> </li> </ol> </p> </section> <section id="CD008901-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses if we were able to combine a sufficient number of trials and if we noted a high degree of statistical heterogeneity (I² over 50%) that could not be reasonably explained. We performed meta‐analyses where multiple trials were available for the same outcome. We also performed sensitivity analyses to assess the robustness of our review results by repeating the analysis with the following adjustments: exclusion of trials with unclear or inadequate allocation concealment; unclear or inadequate blinding of outcomes assessment; and completeness of follow‐up. </p> </section> <section id="CD008901-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>At the 2018 update, we included a summary of findings table for each comparison in the review. The four main comparisons are as follows </p> <p> <ul id="CD008901-list-0020"> <li> <p>standard‐dose rhGH compared to placebo for children and young adults with CF;</p> </li> <li> <p>standard‐dose rhGH compared to no treatment for children and young adults with CF;</p> </li> <li> <p>high‐dose rhGH compared to placebo for children and young adults with CF;</p> </li> <li> <p>high‐dose rhGH compared to standard‐dose rhGH for children and young adults with CF.</p> </li> </ul> </p> <p>We have selected the following seven outcomes, which we consider to be the most important, to include in the tables. </p> <p> <ol id="CD008901-list-0021"> <li> <p>FEV<sub>1</sub> % predicted (change from baseline) </p> </li> <li> <p>FVC % predicted (change from baseline)</p> </li> <li> <p>Height velocity (cm/year) (at the end of the trial)</p> </li> <li> <p>Weight (kg) (change from the baseline)</p> </li> <li> <p>QoL (measured during the trial)</p> </li> <li> <p>FBG (mg/dL) (at the end of the trial)</p> </li> <li> <p>Number of pulmonary exacerbations or hospitalisations (during the trial period)</p> </li> </ol> </p> <p>We used the GRADE approach to assess the certainty of the evidence for each outcome based on the risk of bias within the trials, relevance to our population of interest (indirectness), unexplained heterogeneity or inconsistency, imprecision of the results or high risk of publication bias. We downgraded the evidence once if the risk was serious and twice if the risk was deemed to be very serious. </p> <p>We have reported at the longest available time point (final) in the tables.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008901-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008901-sec-0040"></div> <section id="CD008901-sec-0041"> <h3 class="title">Description of studies</h3> <p>Please see the tables for additional information (<a href="./references#CD008901-sec-0206" title="">Characteristics of included studies</a>; <a href="./references#CD008901-sec-0207" title="">Characteristics of excluded studies</a>). </p> <section id="CD008901-sec-0042"> <h4 class="title">Results of the search</h4> <p>The electronic searches retrieved 40 references. After examination of the titles and abstracts of these references, we eliminated from the review any trials that did not match our inclusion criteria and were clearly ineligible. We obtained full‐text copies of the 24 potentially eligible trials and subjected these to further evaluation. The review authors discussed the eligibility of these trials, resolved any remaining uncertainties by consensus and found eight trials to be eligible. Four trials were included in the initial review (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>), four additional trials previously listed as 'Awaiting classification', were added in the 2018 update of the review after contact with the lead investigator who confirmed that each trial had independent participants (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). </p> <p>We excluded 13 trials from the results of the search of the Cochrane Cystic Fibrosis Trials Register (<a href="./references#CD008901-bbs2-0009" title="AlemzadehR , UpchurchL , McCarthyV . Anabolic effects of growth hormone treatment in young children with cystic fibrosis. Journal of the American College of Nutrition1998;17(5):419-24. [PMID: 9791837]">Alemzadeh 1998</a>; <a href="./references#CD008901-bbs2-0010" title="BucuvalasJC , ChernausekSD , AlfaroMP , KrugS , RitschelW , WilmottRW . Insulin-like growth factor -I enhances linear growth in undernourished prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology1998;26 (Suppl 17):355. [CFGD REGISTER: GN123a] 5500100000001298 BucuvalasJC , ChernausekSD , AlfaroMP , KrugSK , RitschelW , WilmottRW . Effect of insulin-like growth factor-1 treatment in children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2001;33(5):576-81. [CFGD REGISTER: GN123b] 5500100000002045 ">Bucuvalas 2001</a>; <a href="./references#CD008901-bbs2-0011" title="DarmaunD , HayesV , SchaefferD , WelchS , MaurasN . Effects of glutamine and recombinant human growth hormone on protein metabolism in prepubertal children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2004;89(3):1146-52. [CFGD REGISTER: GN90b] SchaefferD , DarmaunD , PunatiJ , MaurasN , HayesVY . Use of glutamine and recombinant human growth hormone (RHGH) in children with cystic fibrosis [abstract]. Pediatric Pulmonology2000;30 (Suppl 20):323. [CFGD REGISTER: GN90a] ">Darmaun 2004</a>; <a href="./references#CD008901-bbs2-0012" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients [abstract]. Pediatric Pulmonology2000;30 (Suppl 20):322-3. [CFGD REGISTER: GN86a] 5500100000001740 EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. [CFGD REGISTER: GN86b] 5500100000002066 ">Eubanks 2002</a>; <a href="./references#CD008901-bbs2-0014" title="HardinDS , SyJP . Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience. Journal of Pediatrics1997;131(1 Pt 2):S65-9. [PMID: 9255232]">Hardin 1997</a>; <a href="./references#CD008901-bbs2-0015" title="HardinDS , StrattonR , KramerJC , Reyes de la RochaS , GovaertsK , WilsonDP . Growth hormone improves weight velocity and height velocity in prepubertal children with cystic fibrosis. Hormone and Metabolic Research1998;30(10):636-41. [PMID: 9851673]">Hardin 1998</a>; <a href="./references#CD008901-bbs2-0016" title="HardinDS , FerkolT , AhnC , DreimaneD , DysonM , MorseM , et al. A retrospective study of growth hormone use in adolescents with cystic fibrosis. Clinical Endocrinology2005;62(5):560-6. [PMID: 15853825]">Hardin 2005c</a>; <a href="./references#CD008901-bbs2-0017" title="HusemanCA , ColomboJL , BrooksMA , SmayJR , GregerNG , SammutPH , et al. Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients. Pediatric Pulmonology1996;22(2):90-5. [PMID: 8875581]">Huseman 1996</a>; <a href="./references#CD008901-bbs2-0018" title="KissnerDG . Role of progestational agents in the treatment of undernourished patients with cystic fibrosis [letter]. Pediatric Pulmonology2000;29(3):244. [CFGD REGISTER: GN93] 5500100000001942 ">Kissner 2000</a>; <a href="./references#CD008901-bbs2-0019" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. [CFGD REGISTER: GN94b] 5500100000002076 MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. [CFGD REGISTER: GN94a] 5500100000001905 ">Marchand 2000</a>; <a href="./references#CD008901-bbs2-0021" title="SackeyAH , TaylorCJ , BarracloughM , WalesJ , PickeringM . Growth hormone as a nutritional adjunct in cystic fibrosis: results of a pilot study. Journal of Human Nutrition1995;8(3):185-91. ">Sackey 1995</a>; <a href="./references#CD008901-bbs2-0022" title="Safai-KuttiS , SelinE , LarssonS , JagenburgR , DenforsI , StenG , et al. Zinc therapy in children with cystic fibrosis. Beitrage Zur Infusiontherapie1991;27:104-14. [CFGD REGISTER: GN36] 5500100000000479 ">Safai‐Kutti 1991</a>; <a href="./references#CD008901-bbs2-0023" title="VanderwelM , HardinDS . Growth hormone normalizes pubertal onset in children with cystic fibrosis. Journal of Pediatric Endocrinology and Metabolism2006;19(3):237-44. [PMID: 16607924]">Vanderwel 2006</a>). Our additional online searches identified one new trial from Iranian Registry of Clinical Trials (<a href="./references#CD008901-bbs2-0013" title="GhergherechiR , RafeeyM , HabibzadehA , ZamaniM , Ansarin Kh, Sadeghi Shabestari M. Recombinant human growth hormone effects on growth in cystic fibrosis. Medical Journal of Tabriz University of Medical Sciences and Health Services. 2017 October;39(4):71-77. ">Ghergherechi 2017</a>) and one trial from the National Institutes of Health clinical trials database (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (<a href="./references#CD008901-bbs2-0020" title="NCT00803179. Growth hormone therapy for wasting in cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00803179 (first received 05 December 2008). ">NCT00803179</a>); both of these were excluded. </p> <p>This process is shown in a PRISMA diagram (<a href="#CD008901-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008901-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008901-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008901-sec-0043"> <h4 class="title">Included studies</h4> <section id="CD008901-sec-0044"> <h5 class="title">Methods</h5> <p>Eight published trials are included in this review (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). One was a quasi‐RCT, where sex‐ and age‐matched pairs were recruited and randomly assigned to treatment (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). </p> <p>Five were RCTs of parallel design (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>) and three trials were cross‐over in design (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>). In two trials, participants were randomised to treatment or no treatment for one year followed by continued treatment for another year; only results from the first year of these trial are included in this review (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). In the third cross‐over trial participants received rhGH or no treatment for six months and then crossed over to the alternative treatment for a further six months without any washout period in between (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>). </p> <p>One of the double‐blinded parallel trials used three treatment arms; low‐dose, high‐dose, and placebo (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). The double‐blind phase in the treatment arms lasted for 24 weeks, following which the controls were randomly assigned to one of the two doses of the rhGH for an additional 24 weeks. </p> <p>The minimum duration of treatment in six trials was one year (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>), while two trials lasted for six months (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0045"> <h5 class="title">Participants and settings</h5> <p>A total of 291 participants provided data for the eight included trials. All trials included diagnosed cases of CF, either by sweat testing or presence of the CFTR gene. The age range of participants was from five years (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>) to 23 years (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>), although most of the trials recruited younger participants in Tanner Stage 1 of sexual maturity staging. The height and weight percentile of the participants ranged from below the 10th to below the 25th percentile for age and gender. Most of the participants were in a stable disease state with no colonisation with <i>Burkholderia cepacia</i> and no recent use of systemic or oral steroids. Most of the trials excluded participants with evidence of glucose intolerance or active CF‐related diabetes (CFRD). All of the trials were carried out at tertiary care CF centres in outpatient settings. Three of the trials were single centre (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>); five were conducted at more than one site (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). Only one of the trials included children receiving enteral nutrition (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>). </p> </section> <section id="CD008901-sec-0046"> <h5 class="title">Interventions</h5> <p>The intervention was daily subcutaneous injections of rhGH. Five trials used the brand Nutropin AQ® (Genentech Inc.) at a dose of 0.3 mg/kg/week (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). One trial used rhGH (Saizen®, Merck Serono S.A.) at a dose of 1 IU/kg/week (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). In a further trial, doses of 0.77 to 0.98 IU/kg/week of rhGH (Genotropin®, Pharmacia GmbH, Stockholm, Sweden) were used (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>). In the remaining trial, two doses of rhGH (somatotropin) were used ‐ low dose, 0.039 mg/kg/day (0.273 mg/kg/week) and high dose, 0.070 mg/kg/day (0.49 mg/kg/week) (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). Only one trial used a placebo as a control (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>); the remaining trials compared the active intervention to no treatment (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). </p> </section> <section id="CD008901-sec-0047"> <h5 class="title">Outcomes measured</h5> <p>All the trials measured at least one of the two of the primary outcomes included in the review ‐ pulmonary function tests and anthropometric parameters. Two trials used validated QoL questionnaires (<a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). Most of the trials addressed blood glucose abnormality, either in quantitative values or information in the text. Four trials measured changes in serum markers, either IGF‐1 or IGFBP3 (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). Two trials measured changes in disease exacerbation or use of antibiotics, or both (<a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). Three trials measured exercise capacity ‐ albeit using different parameters (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). None of the trials evaluated the cost of the therapy, although one trial mentions information on cost‐benefit analysis in the text (<a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). </p> </section> </section> <section id="CD008901-sec-0048"> <h4 class="title">Excluded studies</h4> <p>We excluded 15 trials in total from the review; nine since they were not randomised (<a href="./references#CD008901-bbs2-0009" title="AlemzadehR , UpchurchL , McCarthyV . Anabolic effects of growth hormone treatment in young children with cystic fibrosis. Journal of the American College of Nutrition1998;17(5):419-24. [PMID: 9791837]">Alemzadeh 1998</a>; <a href="./references#CD008901-bbs2-0013" title="GhergherechiR , RafeeyM , HabibzadehA , ZamaniM , Ansarin Kh, Sadeghi Shabestari M. Recombinant human growth hormone effects on growth in cystic fibrosis. Medical Journal of Tabriz University of Medical Sciences and Health Services. 2017 October;39(4):71-77. ">Ghergherechi 2017</a>; <a href="./references#CD008901-bbs2-0014" title="HardinDS , SyJP . Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience. Journal of Pediatrics1997;131(1 Pt 2):S65-9. [PMID: 9255232]">Hardin 1997</a>; <a href="./references#CD008901-bbs2-0015" title="HardinDS , StrattonR , KramerJC , Reyes de la RochaS , GovaertsK , WilsonDP . Growth hormone improves weight velocity and height velocity in prepubertal children with cystic fibrosis. Hormone and Metabolic Research1998;30(10):636-41. [PMID: 9851673]">Hardin 1998</a>; <a href="./references#CD008901-bbs2-0016" title="HardinDS , FerkolT , AhnC , DreimaneD , DysonM , MorseM , et al. A retrospective study of growth hormone use in adolescents with cystic fibrosis. Clinical Endocrinology2005;62(5):560-6. [PMID: 15853825]">Hardin 2005c</a>; <a href="./references#CD008901-bbs2-0017" title="HusemanCA , ColomboJL , BrooksMA , SmayJR , GregerNG , SammutPH , et al. Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients. Pediatric Pulmonology1996;22(2):90-5. [PMID: 8875581]">Huseman 1996</a>; <a href="./references#CD008901-bbs2-0020" title="NCT00803179. Growth hormone therapy for wasting in cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00803179 (first received 05 December 2008). ">NCT00803179</a>; <a href="./references#CD008901-bbs2-0021" title="SackeyAH , TaylorCJ , BarracloughM , WalesJ , PickeringM . Growth hormone as a nutritional adjunct in cystic fibrosis: results of a pilot study. Journal of Human Nutrition1995;8(3):185-91. ">Sackey 1995</a>; <a href="./references#CD008901-bbs2-0023" title="VanderwelM , HardinDS . Growth hormone normalizes pubertal onset in children with cystic fibrosis. Journal of Pediatric Endocrinology and Metabolism2006;19(3):237-44. [PMID: 16607924]">Vanderwel 2006</a>). In six trials the intervention was not appropriate: one used glutamine in conjunction with rhGH (<a href="./references#CD008901-bbs2-0011" title="DarmaunD , HayesV , SchaefferD , WelchS , MaurasN . Effects of glutamine and recombinant human growth hormone on protein metabolism in prepubertal children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2004;89(3):1146-52. [CFGD REGISTER: GN90b] SchaefferD , DarmaunD , PunatiJ , MaurasN , HayesVY . Use of glutamine and recombinant human growth hormone (RHGH) in children with cystic fibrosis [abstract]. Pediatric Pulmonology2000;30 (Suppl 20):323. [CFGD REGISTER: GN90a] ">Darmaun 2004</a>); two used an appetite stimulant (megestrol acetate) (<a href="./references#CD008901-bbs2-0012" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients [abstract]. Pediatric Pulmonology2000;30 (Suppl 20):322-3. [CFGD REGISTER: GN86a] 5500100000001740 EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. [CFGD REGISTER: GN86b] 5500100000002066 ">Eubanks 2002</a>; <a href="./references#CD008901-bbs2-0019" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. [CFGD REGISTER: GN94b] 5500100000002076 MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. [CFGD REGISTER: GN94a] 5500100000001905 ">Marchand 2000</a>); one used progestational agents (<a href="./references#CD008901-bbs2-0018" title="KissnerDG . Role of progestational agents in the treatment of undernourished patients with cystic fibrosis [letter]. Pediatric Pulmonology2000;29(3):244. [CFGD REGISTER: GN93] 5500100000001942 ">Kissner 2000</a>); one used oral zinc supplementation (<a href="./references#CD008901-bbs2-0022" title="Safai-KuttiS , SelinE , LarssonS , JagenburgR , DenforsI , StenG , et al. Zinc therapy in children with cystic fibrosis. Beitrage Zur Infusiontherapie1991;27:104-14. [CFGD REGISTER: GN36] 5500100000000479 ">Safai‐Kutti 1991</a>); and one used IGF‐1 (<a href="./references#CD008901-bbs2-0010" title="BucuvalasJC , ChernausekSD , AlfaroMP , KrugS , RitschelW , WilmottRW . Insulin-like growth factor -I enhances linear growth in undernourished prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology1998;26 (Suppl 17):355. [CFGD REGISTER: GN123a] 5500100000001298 BucuvalasJC , ChernausekSD , AlfaroMP , KrugSK , RitschelW , WilmottRW . Effect of insulin-like growth factor-1 treatment in children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2001;33(5):576-81. [CFGD REGISTER: GN123b] 5500100000002045 ">Bucuvalas 2001</a>). </p> <p>Further information on these trials is available in the <a href="./references#CD008901-sec-0207" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD008901-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>We classified the risk of bias for the eight included trials in this review as previously described (<a href="#CD008901-sec-0030">Assessment of risk of bias in included studies</a>).<br/><br/>We judged all of the included trials as having an 'unclear' overall risk of bias. We based these assessments to a large extent on the inadequate reporting of several of the criteria that are considered to be important in the evaluation of methodological rigour in terms of study design and conduct. For further details, please see the risk of bias tables in <a href="./references#CD008901-sec-0206" title="">Characteristics of included studies</a>, the risk of bias graph (<a href="#CD008901-fig-0002">Figure 2</a>) and the risk of bias summary (<a href="#CD008901-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008901-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008901-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008901-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008901-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008901-sec-0050"> <h4 class="title">Allocation</h4> <section id="CD008901-sec-0051"> <h5 class="title">Generation of allocation sequence</h5> <p>We judged two trials to have a low risk of bias for the generation of allocation sequence (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). Hardin reported use of a computer‐generated random assignment in the 2005a trial (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>). Stalvey reported the use of a permuted block randomisation scheme developed by an interactive voice response development system at each site (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). </p> <p>The remaining trials do not describe details of the generation of allocation sequence and hence we classified these as having an unclear risk of bias (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0052"> <h5 class="title">Concealment of allocation</h5> <p>One trial included a statement "For this open‐label trial, there was no allocation concealment" (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). However, based on the context, it is possible that the authors are referring to blinding rather than concealment of the allocation sequence, and hence we have judged this as unclear risk. None of the remaining trials described how the allocation sequence was concealed, which did not allow us to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment. We therefore judged all eight trials to have an unclear risk of bias for this domain. </p> </section> </section> <section id="CD008901-sec-0053"> <h4 class="title">Blinding</h4> <section id="CD008901-sec-0054"> <h5 class="title">Perfomance bias</h5> <p>In one of the trials, participants were grouped into low‐dose, high‐dose and placebo; it is noted in the manuscript that participants and healthcare providers were blinded and hence the overall judgement is low risk of bias (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> <p>The remaining seven trials are judged to have a high risk of bias (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). In five of these trials the participants and personnel were able to differentiate between treatment groups (e.g. subcutaneous injection versus no treatment) (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>), in two trials no blinding of participants was stated (<a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). </p> </section> <section id="CD008901-sec-0055"> <h5 class="title">Detection bias</h5> <p>None of the eight included trials described any methods to blind outcome assessors and we therefore judge them to have an unclear risk of bias (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). </p> </section> </section> <section id="CD008901-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>We judged five trials as having a low risk of bias (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). There were no reports of dropouts or incomplete data in either Hardin trial from 2005 (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>). In the latest Hardin trial, 61 participants were enrolled and 57 were included in the analyses; the dropouts, two from each group, are accounted for in the paper (<a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). In one cross‐over trial there were no withdrawals and no missing or incomplete data (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>). The Schibler trial describes the withdrawal of one control evaluated for lung transplantation, likely due to worsening of the disease and also has a low risk of bias (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). </p> <p>We judged the remaining trials to have an unclear risk of bias (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). In the earliest Hardin trial, 21 participants were enrolled and two participants dropped out within six weeks of starting the trial (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>). The Schnabel trial reports the analysis of 63 out of the 67 participants enrolled, but no details are provided on the withdrawals (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). The Stalvey trial enrolled 68 participants and reported results on efficacy in 53 participants only (loss of 22% participants); several reasons including loss to follow‐up, death of one participant and improper study practices at one centre were reported for this discrepancy (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). </p> </section> <section id="CD008901-sec-0057"> <h4 class="title">Selective reporting</h4> <p>Although no trial protocols were available, based on information presented in the methods sections of each of the reports, the investigators appear to have reported on all of their stated objectives and expected outcomes, a number of which were pre‐specified inclusion criteria for this systematic review. We therefore judge there to be a low risk of bias from selective reporting for the included trials. </p> </section> <section id="CD008901-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>All of the included trials were supported in some part by pharmaceutical companies, Pharmacia GmbH (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>); Merck Serono SA (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>); Pharmacia GmbH (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>) and Genetech Inc. (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). The effect, if any, of this support on the results is unclear. </p> </section> </section> <section id="CD008901-sec-0059"> <h3 class="title" id="CD008901-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD008901-tbl-0001"><b>Summary of findings 1</b> Standard rhGH compared to placebo for cystic fibrosis in children and young adults</a>; <a href="./full#CD008901-tbl-0002"><b>Summary of findings 2</b> Standard rhGH compared to no treatment for cystic fibrosis in children and young adults</a>; <a href="./full#CD008901-tbl-0003"><b>Summary of findings 3</b> High‐dose rhGH compared to placebo for children and young adults with cystic fibrosis</a>; <a href="./full#CD008901-tbl-0004"><b>Summary of findings 4</b> High‐dose rhGH compared to standard‐dose rhGH for children and young adults with cystic fibrosis</a> </p> <section id="CD008901-sec-0060"> <h4 class="title">Recombinant growth hormone (standard dose) versus placebo</h4> <p>Only one trial (n = 63) was conducted initially over 24 weeks as a double‐blind RCT with two different doses of rhGH compared with placebo followed by another 24 weeks of open‐labelled hormone use (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). Data from the end of the first 24 weeks (double‐blinded) are reported in the review; in this section the data for standard dose of rhGH versus placebo are presented. </p> <section id="CD008901-sec-0061"> <h5 class="title">Primary outcomes</h5> <section id="CD008901-sec-0062"> <h6 class="title">1. Pulmonary function tests</h6> <section id="CD008901-sec-0063"> <p><b>a. FEV<sub>1</sub> </b></p> <p>The trial reported the change in FEV<sub>1</sub> % predicted from baseline to six months (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). There was no difference between the rhGH and placebo groups for this outcome (n = 43), MD 2.50 (95% CI ‐8.60 to 13.60; P = 0.66) (<a href="./references#CD008901-fig-0004" title="">Analysis 1.1</a>) (low‐certainty evidence), or in the z score (n = 43), MD 0.00 (95% CI ‐0.23 to 0.23; P = 1.00) (<a href="./references#CD008901-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD008901-sec-0064"> <p><b>b. FVC</b></p> <p>There was also no significant difference between groups in the change in FVC % predicted from baseline (n = 43) (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>), MD 3.80 (95% CI ‐4.67 to 12.27; P = 0.38) (<a href="./references#CD008901-fig-0006" title="">Analysis 1.3</a>) (low‐certainty evidence). </p> </section> </section> <section id="CD008901-sec-0065"> <h6 class="title">2. Anthropometric parameters</h6> <section id="CD008901-sec-0066"> <p><b>a. Height</b></p> <p>Data for this outcome (n = 43) showed an increase in the height z score between rhGH and placebo, but this was not statistically significant (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>), MD 2.50 (95% CI ‐0.77 to 5.77; P = 0.13) (<a href="./references#CD008901-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD008901-sec-0067"> <p><b>b. Height velocity</b></p> <p>Height velocity at six months was found to be in favour of rhGH (n = 43), MD 2.10 cm/year (95% CI 0.54 to 3.66; P = 0.008) (<a href="./references#CD008901-fig-0008" title="">Analysis 1.5</a>) (low‐certainty evidence) (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0068"> <p><b>c. Weight</b></p> <p>The trial (n = 43) also reported an increase in weight from baseline at six months (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>), but this was not statistically significant, MD 1.00 kg (95% CI ‐0.08 to 2.08; P = 0.07) (<a href="./references#CD008901-fig-0009" title="">Analysis 1.6</a>) (low‐certainty evidence). </p> </section> <section id="CD008901-sec-0069"> <p><b>d. Weight velocity</b></p> <p>The included trial did not report on this outcome (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0070"> <p><b>e. LBM</b></p> <p>The included trial (n = 43) reported data on LBM using DEXA scan at six months (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>), but the difference between treatment and placebo groups in the change from baseline was not statistically significant, MD 1.00 kg (95% CI ‐0.40 to 2.40; P = 0.16) (<a href="./references#CD008901-fig-0010" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD008901-sec-0071"> <h6 class="title">3. QoL</h6> <p>Schnabel also reported QoL using standardised CF health‐related quality of life (HRQoL) questionnaires and reported no major differences among the treatment groups; however investigators did not provide data that could be analysed (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>) (very low‐certainty evidence). </p> </section> </section> <section id="CD008901-sec-0072"> <h5 class="title">Secondary outcomes</h5> <section id="CD008901-sec-0073"> <h6 class="title">1. Impact of rhGH therapy on blood glucose abnormality</h6> <section id="CD008901-sec-0074"> <p><b>a. Impact on fasting insulin levels in non‐diabetic participants</b></p> <p>The included trial did not report on this outcome (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0075"> <p><b>b. FBG and PPBGlevels</b></p> <p>FBG levels were reported at six months (n = 43) (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). Data showed a significant increase in the rhGH treatment group, MD 12.40 mg/dL (95% CI 3.76 to 21.04; P=0.005) (<a href="./references#CD008901-fig-0011" title="">Analysis 1.8</a>) (low‐certainty evidence). Although the increase in FBG is statistically significant in the participants receiving rhGH, this is not clinically suggestive of hyperglycaemia or diabetes. The reported difference in PPBG levels is not statistically significant (n = 43), MD 12.10, 95% CI ‐7.18 to 31.38; P = 0.22) (<a href="./references#CD008901-fig-0012" title="">Analysis 1.9</a>). </p> </section> <section id="CD008901-sec-0076"> <p><b>c. Change in exogenous insulin requirements and blood sugar control in diabetic participants</b></p> <p>None of the participants in the included trial had diabetes (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> </section> <section id="CD008901-sec-0077"> <h6 class="title">2. Muscular strength and exercise capacity</h6> <section id="CD008901-sec-0078"> <p><b>a. Changes in overall muscle strength</b></p> <p>Exercise capacity and muscle strength were measured using a bicycle ergometer (n = 43) (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). Data showed a non‐statistically significant difference, MD 9.80 watts (95% CI ‐0.90 to 20.50; P = 0.07) (<a href="./references#CD008901-fig-0013" title="">Analysis 1.10</a>). Investigators also measured peak oxygen utilisation during exercise (VO2 max) (n = 43) (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>), but results showed no difference between the two groups, MD 10.10 mL/min (95% CI ‐3.85 to 24.05; P = 0.16) (<a href="./references#CD008901-fig-0014" title="">Analysis 1.11</a>). </p> </section> <section id="CD008901-sec-0079"> <p><b>b. Six‐minute walk</b></p> <p>Schnabel did not report on this outcome (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> </section> <section id="CD008901-sec-0080"> <h6 class="title">3. Serum IGF‐1 levels and IGFBP‐3 levels</h6> <p>Schnabel (n = 43) reported levels of IGF‐1 and IGFBP‐3 at six months in z scores (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). There was an expected increase in IGF‐1 with administration of rhGH, MD 1.37 (95% CI 0.68 to 2.06; P = 0.0001) (<a href="./references#CD008901-fig-0015" title="">Analysis 1.12</a>), but limited evidence of an increase in IGFBP‐3, MD 0.65 (95% CI ‐0.10 to 1.40; P = 0.09) (<a href="./references#CD008901-fig-0016" title="">Analysis 1.13</a>). </p> </section> <section id="CD008901-sec-0081"> <h6 class="title">4. Change in disease exacerbation</h6> <section id="CD008901-sec-0082"> <p><b>a. Hospitalisation ‐ frequency and duration</b></p> <p>Schnabel did not report on this outcome (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0083"> <p><b>b. Need for antibiotics</b></p> <p>Schnabel (n = 44) reported similar numbers of pulmonary exacerbations in each of the treatment arms, RR 1.50 (95% CI 0.49 to 4.59; P=0.48) (<a href="./references#CD008901-fig-0017" title="">Analysis 1.14</a>) (low‐certainty evidence). </p> </section> </section> <section id="CD008901-sec-0084"> <h6 class="title">5. Adverse effects</h6> <p>Schnabel (n = 44) reports the number of participants experiencing at least one adverse event in the groups and the number of participants with severe adverse events, but not categorised as outlined in the review protocol. There was no difference in the total number of participants experiencing at least one adverse event between the two groups, RR 1.08 (95% CI 0.67 to 1.72; P = 0.76) (<a href="./references#CD008901-fig-0018" title="">Analysis 1.15</a>). The range of adverse events was wide (pulmonary exacerbation, haemoptysis, pneumothorax, productive cough, Candida sepsis, distal intestinal obstruction syndrome, hyperglycaemia, convulsion, Port‐a‐cath blockage and ligament rupture) but the paper only reported these by the number of events and not by the number of participants experiencing these events so we are not able to analyse these here. </p> <section id="CD008901-sec-0085"> <p><b>a. Mild (requiring no treatment)</b></p> <p>Schnabel did not report on this outcome separate from total adverse events (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0086"> <p><b>b. Moderate (requiring treatment)</b></p> <p>Schnabel reported an equal number of adverse effects observed in all the treatment arms with the commonest adverse effect being pulmonary exacerbations, as reported above (<a href="./references#CD008901-fig-0017" title="">Analysis 1.14</a>). </p> </section> <section id="CD008901-sec-0087"> <p><b>c. Life‐threatening or severe (requiring hospitalisation)</b></p> <p>There was no significant difference in the severe adverse effects reported between the two comparison groups (n = 44), RR 1.25 (95% CI 0.39 to 4.05; P = 0.71) (<a href="./references#CD008901-fig-0018" title="">Analysis 1.15</a>). </p> </section> </section> <section id="CD008901-sec-0088"> <h6 class="title">6. Cost</h6> <p>Schnabel did not report on this outcome (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> </section> </section> <section id="CD008901-sec-0089"> <h4 class="title">Recombinant growth hormone (standard dose) versus no treatment</h4> <p>Seven of the included trials compared the use of daily subcutaneous injections of rhGH with no treatment (n = 228) (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). In the Hütler trial, groups receiving rhGH or no treatment were crossed over after six months; only extractable data from the first treatment period is included in the review (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>). All other trials had a period of at least one year where the intervention or no treatment control were administered. In two trials the treatment group, but not the controls, received rhGH for the first year of the trial and all participants received rhGH in the second year; we only report data at the end of the first year in this review (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). </p> <section id="CD008901-sec-0090"> <h5 class="title">Primary outcomes</h5> <section id="CD008901-sec-0091"> <h6 class="title">1. Pulmonary function tests</h6> <section id="CD008901-sec-0092"> <p><b>a. FEV<sub>1</sub> </b></p> <p>Six trials reported FEV<sub>1</sub> at six or 12 months in various formats (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). </p> <p>Three trials (n = 93) reported absolute values for FEV<sub>1</sub> % predicted at 12 months (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). There was no significant difference found between rhGH and no treatment, MD ‐4.15 (95% CI ‐13.99 to 5.70; P = 0.43) (<a href="./references#CD008901-fig-0019" title="">Analysis 2.1</a>). Heterogeneity was low (I² = 18%). </p> <p>Four trials (n = 104) reported the change from baseline in FEV<sub>1</sub>, one (n = 19) reported using % predicted (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>) and three (n = 85) measured this outcome in L (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>). We analysed these combined data using the SMD. Analysis showed that at six months the change in FEV<sub>1</sub> was not statistically significant, SMD ‐0.32 (95% CI ‐1.06 to 0.41; P = 0.39) with no heterogeneity (I² = 0%). Results were also not significant when data for % predicted and for L were considered separately. However, at 12 months combined results from three trials (n = 94) significantly favoured rhGH, SMD 0.64 (95% CI 0.21 to 1.06; P = 0.003). Results from one trial (n = 19) for the change in FEV<sub>1</sub> % predicted was not significantly different between groups, SMD 0.29 (95% CI ‐0.62 to 1.19) (<a href="./references#CD008901-fig-0020" title="">Analysis 2.2</a>) (very low‐certainty evidence), but the difference in FEV<sub>1</sub> (L) (two trials, 75 participants) was statistically significant, SMD 0.74 (95% CI 0.26 to 1.22). Moderate heterogeneity for the combined data at 12 months (I² = 64%) was caused by the inclusion of participants who were receiving enteral nutrition (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>); the exclusion of these participants resulted in two trials (n = 76) showing a non‐significant effect, SMD 0.44 (95% CI ‐0.02 to 0.90; P = 0.06) with no heterogeneity (I² = 0%) (<a href="./references#CD008901-fig-0020" title="">Analysis 2.2</a>). </p> </section> <section id="CD008901-sec-0093"> <p><b>b. FVC</b></p> <p>Five trials reported data for FVC at six or 12 months as absolute values in % predicted (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>) and change from baseline in % predicted and L (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). </p> <p>Analyses of data for absolute values for FVC % predicted from three trials (n = 93) at 12 months did not show statistically significant results between the two groups, MD 3.05 (95% CI ‐9.50 to 15.60; P = 0.63) (<a href="./references#CD008901-fig-0021" title="">Analysis 2.3</a>). We identified moderate heterogeneity (I² = 62%), likely because of the differences in the baseline condition between the participants across the three trials. The control participants in the Stalvey trial had a significantly higher mean baseline FVC and although both groups showed significantly improved FVC over the duration of the trial, the improvement in the intervention group was smaller (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). </p> <p>Three trials (n = 94) reported the change from baseline in FVC using two different units (% predicted and L), hence we used SMD for the meta‐analysis. It should be noted one small trial (n = 19) was measured at six months (% predicted) with a non‐statistically significant difference between groups, SMD 0.43 (95% CI ‐0.48 to 1.34). This trial additionally reported with two larger trials (which reported L) at 12 months (n = 94) and combined data significantly favoured rhGH therapy, SMD 1.32 (95% CI 0.55 to 2.10) with moderate heterogeneity (I² = 55%). There was an improvement in both units of measurement, SMD 1.00 for % predicted change (95% CI 0.03 to 1.96) (very low‐certainty evidence) and SMD 1.61 L (95% CI 0.17 to 3.06) (<a href="./references#CD008901-fig-0022" title="">Analysis 2.4</a>). </p> </section> <section id="CD008901-sec-0094"> <p><b>c. PI<sub>max</sub> </b></p> <p>One trial (n = 19) reported a significant improvement in PI<sub>max</sub> with rhGH therapy, MD ‐21.00 mm Hg (95% CI ‐28.69 to ‐13.31; P &lt; 0.0001) (<a href="./references#CD008901-fig-0023" title="">Analysis 2.5</a>) (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>). This outcome is not a direct measure of pulmonary function clinically. </p> </section> <section id="CD008901-sec-0095"> <p><b>d. PE<sub>max</sub> </b></p> <p>One trial (n = 28) reported a significant improvement in PE<sub>max</sub> with rhGH therapy, MD 23.00 mm Hg (95% CI 16.89 to 29.11; P &lt; 0.0001) (<a href="./references#CD008901-fig-0024" title="">Analysis 2.6</a>) (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>). This outcome is not a direct measure of pulmonary function clinically. </p> </section> </section> <section id="CD008901-sec-0096"> <h6 class="title">2. Anthropometric parameters</h6> <section id="CD008901-sec-0097"> <p><b>a. Height</b></p> <p>Five trials reported data on height at six or 12 months in a variety of formats.</p> <p>Four trials (n = 131) reported height z score (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). Height z score significantly favoured rhGH over no treatment at 12 months, MD 0.58 (95% CI 0.36 to 0.80; P &lt; 0.0001) with no heterogeneity (I² = 0%) (<a href="./references#CD008901-fig-0025" title="">Analysis 2.7</a>). </p> <p>One trial (n = 10) reported the change from baseline in height (cm) (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>). There was a (not statistically significant) improvement in height at six months, MD 1.40 cm (95% CI ‐0.07 to 2.87; z = 1.87; P = 0.06) (<a href="./references#CD008901-fig-0026" title="">Analysis 2.8</a>). </p> <p><i>b. Height velocity</i> </p> <p>Four trials (n = 156) reported on height velocity (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). Two trials (n = 76) showed a significant difference between rhGH and no treatment in height velocity at six months, MD 4.51 cm/year (95% CI 2.21 to 6.81) but with a significant degree of heterogeneity (I² = 88%) (<a href="./references#CD008901-fig-0027" title="">Analysis 2.9</a>). At 12 months, four trials (n = 156) also showed a significant difference in height velocity, MD 3.53 cm/year (95% CI 2.77 to 4.30; P = 0.09) again with a high degree of heterogeneity (I² = 55%) (<a href="./references#CD008901-fig-0027" title="">Analysis 2.9</a>) (very low‐certaintyevidence). The heterogeneity in both cases was caused by a trial that enrolled participants on enteral nutrition (<a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>). The exclusion of this trial resulted in lower heterogeneity (I² = 37%) but the result was still significant, MD 3.24 cm/year (95% CI 2.51 to 3.97; P = 0.20) (<a href="./references#CD008901-fig-0027" title="">Analysis 2.9</a>). </p> <p>There was also a statistically and clinically significant improvement in height percentile rank documented by one trial (n = 19) (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>), MD 12.20 (95% CI 10.84 to 13.56; P &lt; 0.0001) (<a href="./references#CD008901-fig-0028" title="">Analysis 2.10</a>). </p> </section> <section id="CD008901-sec-0098"> <p><b>c. Weight</b></p> <p>Six trials reported data on changes in weight at six or 12 months in different formats.</p> <p>Four trials (n = 88) reported weight z score (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). Data from the Schibler trial (n = 19) showed a statistically significant difference in weight z score between groups at six months (favouring no treatment), MD ‐0.10 (95% CI ‐0.21 to ‐0.00; P = 0.05) (<a href="./references#CD008901-fig-0029" title="">Analysis 2.11</a>). Results from four trials (n = 88) at 12 months did not show a statistically significant difference between rhGH and no treatment, MD 0.48 (95% CI ‐0.07 to 1.03; P = 0.09) with high heterogeneity (I² = 73%) (<a href="./references#CD008901-fig-0029" title="">Analysis 2.11</a>). Malnutrition in CF is known to worsen with age and one trial enrolled participants with a much older age range than the other trials showed much less weight gain, giving rise to the heterogeneity in the outcome (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). Omitting this trial, three trials (n = 69) showed a significant improvement in weight, MD 0.74 (95% CI 0.32 to 1.17; P = 0.0006) with no heterogeneity (I² = 0%) (<a href="./references#CD008901-fig-0029" title="">Analysis 2.11</a>). </p> <p>Two trials (n = 72) reported the change from baseline in weight (kg) (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). At six months (n = 10), there was no significant difference between groups, MD 1.00 kg (95% CI ‐0.22 to 2.22). In the second trial that reported a difference at 12 months (n = 62), there was a significant difference between groups, MD 1.00 kg (95% CI 0.18 to 1.82) (very low‐certainty evidence)(<a href="./references#CD008901-fig-0030" title="">Analysis 2.12</a>). </p> </section> <section id="CD008901-sec-0099"> <p><b>d. Weight velocity</b></p> <p>Weight velocity was measured in three trials at two different time points (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). Two trials (n = 76) reported a significant increase favouring rhGH at six months, MD 3.12 (95% CI 1.27 to 4.97; P = 0.001) but with a very high level of heterogeneity (I² = 91%) (<a href="./references#CD008901-fig-0031" title="">Analysis 2.13</a>). All three trials (n = 94) reported at 12 months and also demonstrated significant increases in the rhGH groups compared to no treatment, MD 2.82 (95% CI 1.53 to 4.10; P &lt; 0.0001), again with a high level of heterogeneity (I² = 81%) (<a href="./references#CD008901-fig-0031" title="">Analysis 2.13</a>). Despite the heterogeneity of the results in this outcome, the overall effect indicates a consistent improvement in weight velocity with rhGH. </p> <p>One trial (n = 19) reported an improvement in weight percentile with rhGH therapy, MD 5.50, 95% CI 4.02 to 6.98; P &lt; 0.0001) (<a href="./references#CD008901-fig-0032" title="">Analysis 2.14</a>) (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>). </p> </section> <section id="CD008901-sec-0100"> <p><b>e. LBM</b></p> <p>All seven trials in this comparison reported changes in LBM by DEXA scan; two trials reported at six months (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>) and six trials at 12 months (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). There was a statistically significant improvement in LBM at six months (three trials, 90 participants), MD 2.57 (95% CI 2.01 to 3.12; P &lt; 0.00001) with little heterogeneity (I² = 28%) (<a href="./references#CD008901-fig-0033" title="">Analysis 2.15</a>). At 12 months five trials (n = 191) reported data for children who were prepubertal at trial entry and found a significant result in favour of rhGH, MD 2.12 (95% CI 1.13 to 3.10; P &lt; 0.0001) but with a high level of heterogeneity (I² = 87%) (<a href="./references#CD008901-fig-0033" title="">Analysis 2.15</a>). One trial (n = 19) reported on children who were post‐pubertal at the start of the trial and this result was also significant at 12 months, MD 2.50 (95% CI 1.85 to 3.15; P &lt; 0.00001). Although the results at 12 months for prepubertal children show severe heterogeneity amongst the trials, all results support an improvement and the differences in effect size are probably due to the small sample size and differences from the included children (<a href="./references#CD008901-fig-0033" title="">Analysis 2.15</a>). One trial reported lean mass (LM) only in the text (<a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). </p> </section> </section> <section id="CD008901-sec-0101"> <h6 class="title">3. QoL</h6> <p>One multicentre trial (n = 57) measured QoL by the change in HRQoL score and in Body Image Score (<a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). While the change in HRQoL was not different between groups, MD 0.10 (95% CI ‐0.32 to 0.52; P = 0.64) (very low‐certainty evidence), the difference for the change in Body Image Score favoured rhGH, MD 0.50 (95% CI 0.03 to 0.97; P = 0.04) (<a href="./references#CD008901-fig-0034" title="">Analysis 2.16</a>). </p> </section> </section> <section id="CD008901-sec-0102"> <h5 class="title">Secondary outcomes</h5> <section id="CD008901-sec-0103"> <h6 class="title">1. Impact of rhGH therapy on blood glucose abnormality</h6> <section id="CD008901-sec-0104"> <p><b>a. Impact on fasting insulin levels in non‐diabetic participants</b></p> <p>Serum insulin levels were measured in two trials (n = 73) (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). There was a statistically significant difference between the two groups as reported by one trial (n = 19) at six months, MD 3.10 μU/mL, 95% CI 2.40 to 3.80; P &lt; 0.0001), but not when data from both trials were combined at 12 months, MD 1.55 μU/mL (95% CI ‐0.60 to 3.70; P = 0.16) with approaching moderate heterogeneity (I² = 49%) (<a href="./references#CD008901-fig-0035" title="">Analysis 2.17</a>). </p> </section> <section id="CD008901-sec-0105"> <p><b>b. FBG and PPBG levels</b></p> <p>Three trials (n = 92) report FBG levels (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). One trial (n = 19) reported at six months (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>) and three trials (n = 92) at 12 months (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>); at neither time point did data show a significant change in FBG levels between treatment with rhGH and no treatment, MD 4.00 mg/dL (95% CI ‐12.57 to 20.57; P = 0.64) and MD 3.20 mg/dL (95% CI ‐6.09 to 12.49; P = 0.50) (very low‐certainty evidence) respectively. However, one trial (n = 19) contributing data to the 12‐month time point showed a significant result in favour of rhGH, MD 12.50 mg/dL (95% CI 5.12 to 19.88; P = 0.0009) (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>); this difference is not clinically relevant as diagnosis of glucose intolerance can be made only if fasting blood glucose is greater than 126 mg/dL. There is also a significant variation in the age range of the participants in the trials reporting at 12 months; in the Schibler trial, ages ranged from 10 years to 23 years and in the Hardin and Stalvey trials, the ages ranged from 5.2 years to 13.4 years (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). It is possible that the older age group represents an advancement of the disease that is also associated with an increased incidence of glucose intolerance. Therefore, there is unclear evidence for the effect of rhGH on fasting blood glucose (<a href="./references#CD008901-fig-0036" title="">Analysis 2.18</a>). </p> <p>Two trials (n = 38) reported data on PPBG levels (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). One trial (n = 19) reported no statistically significant difference in the PPBG levels between groups at six months, MD 5.00 mg/dL (95% CI ‐2.20 to 12.20); this was also true for both trials (n = 38) at 12 months, MD ‐10.75 (95% CI ‐32.74 to 11.25; P = 0.17) with low heterogeneity (I² = 35%) (<a href="./references#CD008901-fig-0037" title="">Analysis 2.19</a>). As previously noted, there are differences in the baseline characteristics of the participants in the Schibler trial (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). </p> <p>In other outcomes related to blood glucose control in non‐diabetic participants, in one trial (n = 19) there was no difference in the haemoglobin A1c levels at six months, MD 0.10% (95% CI ‐0.44 to 0.64; P = 0.72) or at 12 months, MD ‐0.30% (95% CI ‐0.66 to 0.06; P = 0.10) (<a href="./references#CD008901-fig-0038" title="">Analysis 2.20</a>) (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>). Additionally, a further trial (n = 19) reported no difference in the change in HbA1c from baseline between groups, MD 0.14% (95% CI ‐0.30 to 0.58; P = 0.54) (<a href="./references#CD008901-fig-0039" title="">Analysis 2.21</a>) (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). </p> </section> <section id="CD008901-sec-0106"> <p><b>c. Change in exogenous insulin requirements and blood sugar control in diabetic participants</b></p> <p>One trial included five participants with impaired glucose tolerance (IGT) (three in the treatment group and two in the control group) (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). Two participants in the treatment group had normal oral glucose tolerance tests (OGTT) at the end of the trial. In each of the trial groups, three participants developed IGT and one developed CF‐related diabetes mellitus (CFRD) at the end of the treatment period (12 months). On further follow‐up to 18 months without any intervention, two additional participants in the rhGH treatment group developed IGT and one CFRD. At a similar follow‐up in the control group, one participant developed IGT. Other trials excluded participants with IGT or diabetes and do not report the incidence of new cases. </p> </section> </section> <section id="CD008901-sec-0107"> <h6 class="title">2. Muscular strength and exercise capacity</h6> <section id="CD008901-sec-0108"> <p><b>a. Changes in overall muscle strength</b></p> <p>Exercise capacity and muscle strength were measured in two trials (n = 29) using a bicycle ergometer (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). </p> <p>The trial by Schibler reported an increase in the maximum exercise capacity, representing an increase in muscle mass, in favour of the rhGH treatment group at both six months, MD 23.10 watts (95% CI 15.58 to 30.62; P &lt; 0.0001) and at 12 months, MD 31.90 watts (95% CI 22.68 to 41.12; P = 0.02) (<a href="./references#CD008901-fig-0040" title="">Analysis 2.22</a>). </p> <p>The paper by Hütler provided a graph showing the increase in the peak power output in terms of absolute (18%) and age‐predicted (14%) values (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>). Both trials measured VO2 max, albeit in different units (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). Results from one trial (n = 10) shows a statistically significant improvement at six months, MD 3.65 mL/min (95% CI 0.60 to 6.70; P &lt; 0.02) (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>) and from the second trial at 12 months (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>), MD 6.10 mL/kg/min, 95% CI 4.29 to 7.91; P &lt; 0.00001) in favour of rhGH treatment (<a href="./references#CD008901-fig-0041" title="">Analysis 2.23</a>). </p> </section> <section id="CD008901-sec-0109"> <p><b>b. Six‐minute walk</b></p> <p>Stalvey (n = 56) measured exercise capacity using the six‐minute walk test (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). At 12 months, there was no statistically significant difference between the 29 participants treated with rhGH versus the 27 participants who received no treatment, MD 25.90 m (95% CI ‐43.57 to 95.37; P = 0.46) (<a href="./references#CD008901-fig-0042" title="">Analysis 2.24</a>). </p> </section> </section> <section id="CD008901-sec-0110"> <h6 class="title">3. Serum IGF‐1 levels and IGFBP‐3 levels</h6> <p>Serum IGF‐1 levels were reported in three trials (n = 69) (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>). There was a statistically significant increase in the levels as reported by one trial (n = 19) at six months, MD 152.00 ng/mL (95% CI 62.89 to 241.11; P = 0.0008) (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>). Combined data from three trials (n = 69) at 12 months also showed significantly higher serum IGF‐1 levels in the rhGH group, MD 198.17 ng/mL (95% CI 135.59 to 260.74; P &lt; 0.00001) with moderate heterogeneity (I² = 51%) (<a href="./references#CD008901-fig-0043" title="">Analysis 2.25</a>). </p> </section> <section id="CD008901-sec-0111"> <h6 class="title">4. Change in disease exacerbation</h6> <section id="CD008901-sec-0112"> <p><b>a. Hospitalisation ‐ frequency and duration</b></p> <p>Three trials (n = 94) reported hospitalisation events at 12 months (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). There were significantly fewer hospitalisations with rhGH therapy than with no treatment, MD ‐1.34 (95% CI ‐1.75 to ‐0.93; P &lt;0.0001) (<a href="./references#CD008901-fig-0044" title="">Analysis 2.26</a>) (very low‐certainty evidence). </p> </section> <section id="CD008901-sec-0113"> <p><b>b. Need for antibiotics ‐ oral and intravenous</b></p> <p>Stalvey stated that the number of pulmonary exacerbations was reported equally by the two groups (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). </p> </section> </section> <section id="CD008901-sec-0114"> <h6 class="title">5. Adverse effects</h6> <p>Only one trial (n = 68) reported data for adverse events (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). Drug‐related adverse events were experienced by 10 participants RR 18.73 (95% CI 1.14 to 307.37) (<a href="./references#CD008901-fig-0045" title="">Analysis 2.27</a>). </p> <section id="CD008901-sec-0115"> <p><b>a. Mild, requiring no treatment</b></p> <p>None of the trials mentions the presence of adverse effects which did not require treatment. It is important to mention that subcutaneous injection of rhGH can be perceived as a burden of treatment and Stalvey stated that seven participants reported injection‐site bruising, RR 13.38 (95% CI 0.79 to 225.34; P = 0.07) (<a href="./references#CD008901-fig-0045" title="">Analysis 2.27</a>). </p> </section> <section id="CD008901-sec-0116"> <p><b>b. Moderate, requiring treatment</b></p> <p>Stalvey reported a similar number of pulmonary exacerbations in the two groups. Additionally, five participants in the rhGH group and seven participants in the control group experienced hyperglycaemia, RR 0.63 (95% CI 0.22 to 1.80) (<a href="./references#CD008901-fig-0045" title="">Analysis 2.27</a>); one of those in the rhGH group had to discontinue the trial (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). One additional participant in the rhGH group had papilledema and headache after five months of rhGH therapy, RR 2.68 (95% CI 0.11 to 63.45; P = 0.54) (<a href="./references#CD008901-fig-0045" title="">Analysis 2.27</a>); the authors conclude this event was rhGH therapy‐related benign intracranial hypertension which resolved with discontinuation of treatment (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). </p> </section> <section id="CD008901-sec-0117"> <p><b>c. Life‐threatening or severe (requiring hospitalisation)</b></p> <p>Stalvey reported one death due to respiratory failure three months after the 12‐month visit, RR 2.68 (95% CI 0.11 to 63.45); however, the authors postulate this is unrelated to the trial (<a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). Hospitalisations as a result of disease exacerbations have been reported earlier. </p> </section> </section> <section id="CD008901-sec-0118"> <h6 class="title">6. Cost</h6> <p>There was a difference in reports on the cost‐benefit analysis of therapy. Therapy with rhGh is expensive and Schibler reports that the cost of the treatment may not be justified for the modest increase in exercise capacity and LBM (<a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). Conversely, in 2006 Hardin reported that the cost of therapy may be justified based on the decrease in the number of hospitalisations (<a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>). </p> </section> </section> </section> <section id="CD008901-sec-0119"> <h4 class="title">High‐dose rhGH versus placebo</h4> <p>One trial reported the use of high‐dose rhGH treatment compared with placebo with data reported at six months (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). The group of participants receiving placebo in this comparison are the same as that used in the prior comparison with the standard dose. </p> <section id="CD008901-sec-0120"> <h5 class="title">Primary outcomes</h5> <section id="CD008901-sec-0121"> <h6 class="title">1. Pulmonary function tests</h6> <section id="CD008901-sec-0122"> <p><b>a. FEV<sub>1</sub> </b></p> <p>The trial (n = 41) reported that there was no statistically significant difference between the high‐dose rhGH group and controls in the change from baseline in FEV<sub>1</sub> % predicted, MD 3.30 (95% CI ‐8.16 to 14.76; P = 0.57) (<a href="./references#CD008901-fig-0046" title="">Analysis 3.1</a>) (low‐certainty evidence) or change in FEV<sub>1</sub> z score, MD ‐0.01 (95% CI ‐0.24 to 0.22; P = 0.93) (<a href="./references#CD008901-fig-0047" title="">Analysis 3.2</a>). </p> </section> <section id="CD008901-sec-0123"> <p><b>b. FVC</b></p> <p>Similarly, there was no statistically significant difference between high‐dose rhGH participants and controls in FVC % predicted (n = 41), MD 6.70 (95% CI ‐1.41 to 14.81; P = 0.11) (<a href="./references#CD008901-fig-0048" title="">Analysis 3.3</a>) (low‐certainty evidence). </p> </section> </section> <section id="CD008901-sec-0124"> <h6 class="title">2. Anthropometric parameters</h6> <section id="CD008901-sec-0125"> <p><b>a. Height</b></p> <p>Data were not available for height in this trial (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0126"> <p><b>b. Height velocity</b></p> <p>There was a statistically significant difference in the change from baseline in height velocity when measured with z score with rhGH treatment (n = 41), MD 3.60 (95% CI 0.30 to 6.90; P = 0.03) (<a href="./references#CD008901-fig-0049" title="">Analysis 3.4</a>) and also with cm/year (n = 41), MD 3.30 cm/year (95% CI 1.17 to 5.43; P = 0.002) (<a href="./references#CD008901-fig-0050" title="">Analysis 3.5</a>) (low‐certainty evidence). </p> </section> <section id="CD008901-sec-0127"> <p><b>c. Weight</b></p> <p>The trial (n = 41) noted no significant difference between groups in the change in weight from baseline, MD 0.80 kg (95% CI ‐0.44 to 2.04; P = 0.21) (<a href="./references#CD008901-fig-0051" title="">Analysis 3.6</a>) (low‐certainty evidence). </p> </section> <section id="CD008901-sec-0128"> <p><b>d. Weight velocity</b></p> <p>No data for weight velocity were available for analysis (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0129"> <p><b>e. LBM</b></p> <p>No statistically significant difference in LBM was seen between the high‐dose rhGH group and the placebo group (n = 41), MD 0.80 (95% CI ‐0.67 to 2.27; P = 0.29) (<a href="./references#CD008901-fig-0052" title="">Analysis 3.7</a>). </p> </section> </section> <section id="CD008901-sec-0130"> <h6 class="title">3. QoL</h6> <p>The Schnabel trial also reported QoL using standardised CF HRQoL questionnaires but did not provide data we could enter into the analysis (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). Within the published paper, Schnabel reported no major differences between the treatment groups (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>) (very low‐certainty evidence). </p> </section> </section> <section id="CD008901-sec-0131"> <h5 class="title">Secondary outcomes</h5> <section id="CD008901-sec-0132"> <h6 class="title">1. Impact of rhGH therapy on blood glucose abnormality</h6> <section id="CD008901-sec-0133"> <p><b>a. Impact on fasting insulin levels in non‐diabetic participants</b></p> <p>No data are available for this outcome (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0134"> <p><b>b. FBG and PPBG levels</b></p> <p>Whilst there was limited evidence of a difference in the FBG levels in the high‐dose rhGH group, MD 8.00 mg/dL (95% CI ‐0.30 to 16.30; P = 0.06) (<a href="./references#CD008901-fig-0053" title="">Analysis 3.8</a>) (low‐quality evidence), this was not supported in PPBG, MD 4.60 mg/dL (95% CI ‐23.32 to 32.52; P = 0.75) (<a href="./references#CD008901-fig-0054" title="">Analysis 3.9</a>). </p> </section> <section id="CD008901-sec-0135"> <p><b>c. Change in exogenous insulin requirements and blood sugar control in diabetic participants</b></p> <p>None of the participants in the Schnabel trial was diabetic (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> </section> <section id="CD008901-sec-0136"> <h6 class="title">2. Muscular strength and exercise capacity</h6> <section id="CD008901-sec-0137"> <p><b>a. Changes in overall muscle strength</b></p> <p>Schnabel (n = 41) evaluated muscle strength using bicycle ergometry (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). No significant difference was found in the exercise capacity between the two groups, MD 4.40 watts (95% CI ‐13.20 to 22.00; P = 0.62) (<a href="./references#CD008901-fig-0055" title="">Analysis 3.10</a>) or VO2 max, MD 24.00 mL/min (95% CI ‐10.61 to 58.61; P = 0.17) (<a href="./references#CD008901-fig-0056" title="">Analysis 3.11</a>). </p> </section> <section id="CD008901-sec-0138"> <p><b>b. Six‐minute walk</b></p> <p>This test was not used in the Schnabel trial (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> </section> <section id="CD008901-sec-0139"> <h6 class="title">3. Serum IGF‐1 levels and IGFBP‐3 levels</h6> <p>Comparison of serum hormone levels showed significant differences between high‐dose rhGH and placebo in favour of high‐dose rhGH treatment: IGF‐1 (z scores), MD 2.03 (95% CI 1.18 to 2.88; P &lt; 0.0001) (<a href="./references#CD008901-fig-0057" title="">Analysis 3.12</a>); and IGFBP‐3 (z scores), MD 0.81 (95% CI 0.11 to 1.51; P = 0.02) (<a href="./references#CD008901-fig-0058" title="">Analysis 3.13</a>). </p> </section> <section id="CD008901-sec-0140"> <h6 class="title">4. Change in disease exacerbation</h6> <p>Hospitalisation and antibiotic usage, oral or intravenous, were not reported by Schnabel (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). However, the report does state that pulmonary exacerbations were the most commonly observed category of adverse events, RR 1.93 (95% CI 0.66 to 5.61; P = 0.21) (<a href="./references#CD008901-fig-0059" title="">Analysis 3.14</a>) (low‐certainty evidence). </p> </section> <section id="CD008901-sec-0141"> <h6 class="title">5. Adverse effects</h6> <p>Schnabel reports the number of participants experiencing at least one adverse event in the groups and the number of participants with severe adverse events, but not categorised as outlined in our review protocol. There was no difference in the total number of participants experiencing at least one adverse event between the two groups, RR 1.02 (95% CI 0.62 to 1.67; P = 0.95) (<a href="./references#CD008901-fig-0060" title="">Analysis 3.15</a>). The range of adverse events was wide (pulmonary exacerbation, haemoptysis, pneumothorax, productive cough, Candida sepsis, distal intestinal obstruction syndrome, hyperglycaemia, convulsion, Port‐a‐cath blockage and ligament rupture) but the paper only reported these by the number of events and not by the number of participants experiencing these events so we are not able to analyse these here. </p> <section id="CD008901-sec-0142"> <p><b>a. Mild, requiring no treatment</b></p> <p>Schnabel did not report on this outcome separate from total adverse events (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0143"> <p><b>b. Moderate, requiring treatment</b></p> <p>Schnabel reported an equal number of adverse effects observed in all the treatment arms with the commonest adverse effect being pulmonary exacerbations as reported above (<a href="./references#CD008901-fig-0059" title="">Analysis 3.14</a>). </p> </section> <section id="CD008901-sec-0144"> <p><b>c. Life‐threatening or severe (requiring hospitalisation)</b></p> <p>There was no significant difference in the severe adverse effects reported between the two comparison groups, or for severe adverse events, RR 1.10 (95% CI 0.32 to 3.83; P = 0.88) (<a href="./references#CD008901-fig-0060" title="">Analysis 3.15</a>). </p> </section> </section> <section id="CD008901-sec-0145"> <h6 class="title">6. Cost</h6> <p>No data were presented on the cost of the therapy by the Schnabel study (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> </section> </section> <section id="CD008901-sec-0146"> <h4 class="title">High‐dose versus standard‐dose rhGH</h4> <p>One study compared high‐dose rhGH versus standard‐dose rhGH (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). The group of participants receiving high‐dose and standard‐dose rhGH in this comparison are the same as those presented in the prior comparisons using high‐dose and standard‐dose compared to placebo. </p> <section id="CD008901-sec-0147"> <h5 class="title">Primary outcomes</h5> <section id="CD008901-sec-0148"> <h6 class="title">1. Pulmonary function tests</h6> <section id="CD008901-sec-0149"> <p><b>a. FEV<sub>1</sub> </b></p> <p>Schnabel (n = 42) found no statistical difference between high‐dose and the standard‐dose rhGH participants for the change from baseline in FEV<sub>1</sub> % predicted, MD 1.20 (95% CI ‐1.04 to 3.44; P = 0.29) (<a href="./references#CD008901-fig-0061" title="">Analysis 4.1</a>) (low‐certainty evidence) or in FEV<sub>1</sub> z score, MD ‐0.01 (95% CI ‐0.20 to 0.18; P = 0.92) (<a href="./references#CD008901-fig-0062" title="">Analysis 4.2</a>). </p> </section> <section id="CD008901-sec-0150"> <p><b>b. FVC</b></p> <p>Likewise, Schnabel (n = 42) found no statistically significant difference in FVC % predicted between the high‐dose and the standard‐dose groups, MD 6.70 (95% CI ‐1.29 to 14.69; P = 0.10) (<a href="./references#CD008901-fig-0063" title="">Analysis 4.3</a>) (low‐certainty evidence). </p> </section> </section> <section id="CD008901-sec-0151"> <h6 class="title">2. Anthropometric parameters</h6> <section id="CD008901-sec-0152"> <p><b>a. Height</b></p> <p>Data on absolute height were not reported in the Schnabel trial (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0153"> <p><b>b. Height velocity</b></p> <p>Schnabel (n = 42) found a significant improvement height velocity z score in the high‐dose rhGH group compared to standard‐dose, MD 1.10 (95% CI ‐0.51 to 2.71; P = 0.18) (<a href="./references#CD008901-fig-0064" title="">Analysis 4.4</a>) and also when measured in cm/year, MD 1.20 cm/year (95% CI ‐1.04 to 3.44; P = 0.29) (<a href="./references#CD008901-fig-0065" title="">Analysis 4.5</a>) (low‐certainty evidence). </p> </section> <section id="CD008901-sec-0154"> <p><b>c. Weight</b></p> <p>No significant difference in the change from the baseline in weight was found between high‐dose rhGh and standard‐dose therapy, MD ‐0.20 kg (95% CI ‐1.48 to 1.08; P = 0.76) (<a href="./references#CD008901-fig-0066" title="">Analysis 4.6</a>) (low‐certainty evidence). </p> </section> <section id="CD008901-sec-0155"> <p><b>d. Weight velocity</b></p> <p>No data on this outcome were reported in the Schnabel trial (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0156"> <p><b>e. LBM</b></p> <p>No significant difference was found in the LBM between the high‐dose and the standard‐dose group, MD ‐0.20 kg (95% CI ‐1.69 to 1.29; P = 0.79) (<a href="./references#CD008901-fig-0067" title="">Analysis 4.7</a>). </p> </section> </section> <section id="CD008901-sec-0157"> <h6 class="title">3. QoL</h6> <p>No data on this outcome were reported in the Schnabel trial (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> </section> <section id="CD008901-sec-0158"> <h5 class="title">Secondary outcomes</h5> <section id="CD008901-sec-0159"> <h6 class="title">1. Impact of rhGH therapy on blood glucose abnormality</h6> <section id="CD008901-sec-0160"> <p><b>a. Impact on fasting insulin levels in non‐diabetic participants</b></p> <p>These data were not reported in the Schnabel trial (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0161"> <p><b>b. FBG and PPBG levels</b></p> <p>No significant differences were found in FBG levels, MD ‐4.40 mg/dL (95% CI ‐13.05 to 4.25; P = 0.32) (<a href="./references#CD008901-fig-0068" title="">Analysis 4.8</a>) (low‐certainty evidence) or PPBG, MD ‐7.50 mg/dL (95% CI ‐38.36 to 23.36; P = 0.63) (<a href="./references#CD008901-fig-0069" title="">Analysis 4.9</a>). </p> </section> <section id="CD008901-sec-0162"> <p><b>c. Change in exogenous insulin requirements and blood sugar control in diabetic participants</b></p> <p>None of the participants in the Schnabel trial was diabetic or on insulin treatment (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> </section> <section id="CD008901-sec-0163"> <h6 class="title">2. Muscular strength and exercise capacity</h6> <section id="CD008901-sec-0164"> <p><b>a. Changes in overall muscle strength</b></p> <p>Muscle strength was measured by bicycle ergometry (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). Schnabel (n = 42) found no significant differences between the two groups in exercise capacity, MD ‐5.40 (95% CI ‐22.96 to 12.16; P = 0.55) (<a href="./references#CD008901-fig-0070" title="">Analysis 4.10</a>) or VO2 max, MD 13.90 (95% CI ‐21.97 to 49.77; P = 0.45) (<a href="./references#CD008901-fig-0071" title="">Analysis 4.11</a>). </p> </section> <section id="CD008901-sec-0165"> <p><b>b. Six‐minute walk</b></p> <p>This test was not used in the Schnabel trial (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> </section> <section id="CD008901-sec-0166"> <h6 class="title">3. Serum IGF‐1 levels and IGFBP‐3 levels</h6> <p>Schnabel (n = 42) reported a statistically significant difference in the IGF‐1 levels (z scores) in favour of the high‐dose rhGH therapy, MD 2.03 (95% CI 1.18 to 2.88; P &lt; 0.00001) (<a href="./references#CD008901-fig-0072" title="">Analysis 4.12</a>) and IGFBP‐3 levels (z scores), MD 0.81 (95% CI 0.11 to 1.51; P = 0.02) (<a href="./references#CD008901-fig-0073" title="">Analysis 4.13</a>). </p> </section> <section id="CD008901-sec-0167"> <h6 class="title">4. Change in disease exacerbation</h6> <p>No data are reported on the hospitalisation or use of oral or intravenous antibiotics in the Schnabel trial (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). However, the report does state that pulmonary exacerbations were the most commonly observed category of adverse events, RR 1.28 (95% CI 0.52 to 3.18; P = 0.59) (<a href="./references#CD008901-fig-0074" title="">Analysis 4.14</a>) (low‐certainty evidence). </p> </section> <section id="CD008901-sec-0168"> <h6 class="title">5. Adverse effects</h6> <p>Schnabel reports the number of participants experiencing at least one adverse event in the groups and the number of participants with severe adverse events, but not categorised as outlined in our review protocol. There was no difference in the total number of participants experiencing at least one adverse event between the two groups, RR 0.94 (95% CI 0.58 to 1.52; P = 0.81) (<a href="./references#CD008901-fig-0075" title="">Analysis 4.15</a>). The range of adverse events was wide (pulmonary exacerbation, haemoptysis, pneumothorax, productive cough, Candida sepsis, distal intestinal obstruction syndrome, hyperglycaemia, convulsion, Port‐a‐cath blockage and ligament rupture) but the paper only reported these by the number of events and not by the number of participants experiencing these events so we are not able to analyse these here. </p> <section id="CD008901-sec-0169"> <p><b>a. Mild, requiring no treatment</b></p> <p>Schnabel did not report on this outcome separate from total adverse events (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> <section id="CD008901-sec-0170"> <p><b>b. Moderate, requiring treatment</b></p> <p>Schnabel reported an equal number of adverse effects observed in all the treatment arms with the commonest adverse effect being pulmonary exacerbations as reported above (<a href="./references#CD008901-fig-0074" title="">Analysis 4.14</a>). </p> </section> <section id="CD008901-sec-0171"> <p><b>c. Life‐threatening or severe (requiring hospitalisation)</b></p> <p>There was no significant difference in the severe adverse effects reported between the two comparison groups, or for severe adverse events, RR 0.88 (95% CI 0.27 to 2.83; P = 0.83) (<a href="./references#CD008901-fig-0075" title="">Analysis 4.15</a>). </p> </section> </section> <section id="CD008901-sec-0172"> <h6 class="title">6. Cost</h6> <p>This outcome is not reported in the Schnabel trial (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008901-sec-0173" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008901-sec-0173"></div> <section id="CD008901-sec-0174"> <h3 class="title" id="CD008901-sec-0174">Summary of main results</h3> <p>Eight trials with a total 275 participants were included in the review. Seven trials used a standard dose of rhGH of approximately 0.3 mg/kg/week compared with no treatment (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>); one of these trials had three treatment arms and compared placebo, standard dose (0.3 mg/kg/week) and high dose (0.5 mg/kg/week) (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). The intervention was administered by daily subcutaneous injections. Six trials included participants for a minimum of 12 months in the randomised phase followed by either open‐label administration for a longer period or clinical follow‐up without treatment administration. The review includes data up to 12 months for these trials (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0002" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN265d] ">Hardin 2005a</a>; <a href="./references#CD008901-bbs2-0003" title="HardinDS , AhnC , PrestidgeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2005;18(6):589-95. [CFGD REGISTER: GN122d] ">Hardin 2005b</a>; <a href="./references#CD008901-bbs2-0004" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonolgy2004;38(Suppl 27):343. [CENTRAL: CN-01400578] [CFGD REGISTER: GN265c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN265e] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Online Supplement to 'Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial'. [online]. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9 Online. [CENTRAL: CN-00593083] [CFGD REGISTER: GN265f] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;Suppl 22:338. [CENTRAL: CN-00362183] [CFGD REGISTER: GN265a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study [abstract]. Pediatric Pulmonology2002;34 (Suppl 24):337. [CFGD REGISTER: GN265b] ">Hardin 2006</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>; <a href="./references#CD008901-bbs2-0008" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 (Suppl 31):368. [GN128b]StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] [DOI: 10.1002/ppul.21546] [PMID: 21905270]StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 (Suppl 30):393. [CFGD REGISTER: GN128a] ">Stalvey 2012</a>). Two included trials had a randomised phase lasting for six months only (<a href="./references#CD008901-bbs2-0005" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl 1):S17. [CENTRAL: CN-00494036] [CFGD REGISTER: GN125b] HütlerM , SchnabelD , StaabD , TackeA , WahnU , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] ">Hütler 2002</a>; <a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>), while two other 12‐month trials also reported data at six months (<a href="./references#CD008901-bbs2-0001" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26(Suppl 17):357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , et al. Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122b] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. [CFGD REGISTER: GN264] NCT00256555. Growth Hormone Treatment Study in Children With Cystic Fibrosis. https://clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). ">Hardin 2001</a>; <a href="./references#CD008901-bbs2-0006" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone [abstract]. In: Proceedings of the 12th European Respiratory Society Annual Congress; 2002 Sept 14-18; Stockholm. 2002:P3287. [GN121b]SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Diseases of Childhood2003;88(12):1078-81. [CFGD REGISTER: GN121c] von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF) [abstract]. In: Proceedings of the 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland. 1997:132. [GN121a]">Schibler 2003</a>). Data from the open‐label phase were not included in the analysis or the review. </p> <p>The most important indicator of the pulmonary prognosis in CF is FEV<sub>1</sub>. In the trial comparing standard‐dose, high‐dose and placebo, there was no statistically significant change in the pulmonary parameters at six months (<a href="./references#CD008901-fig-0004" title="">Analysis 1.1</a>; <a href="./references#CD008901-fig-0005" title="">Analysis 1.2</a>; <a href="./references#CD008901-fig-0006" title="">Analysis 1.3</a>; <a href="./references#CD008901-fig-0046" title="">Analysis 3.1</a>; <a href="./references#CD008901-fig-0047" title="">Analysis 3.2</a>; <a href="./references#CD008901-fig-0048" title="">Analysis 3.3</a>) (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>). Similar results were seen in the rhGH versus no treatment group at six months as well as the absolute measurements of FEV<sub>1</sub> and FVC (<a href="./references#CD008901-fig-0019" title="">Analysis 2.1</a>; <a href="./references#CD008901-fig-0021" title="">Analysis 2.3</a>). However, there was a statistically significant difference in the change in FEV<sub>1</sub> and FVC at 12 months as compared to baseline in the rhGH versus no treatment groups, albeit with significant heterogeneity in the results (<a href="./references#CD008901-fig-0020" title="">Analysis 2.2</a>; <a href="./references#CD008901-fig-0022" title="">Analysis 2.4</a>). </p> <p>The association between severity of lung disease and body growth, nutritional status and LBM in CF is well established in multiple studies. Individuals with higher anthropometric parameters and LBM are known to have better pulmonary function. There was a statistically significant improvement in at least one of the height measurements at six and 12 months for all comparisons (<a href="./references#CD008901-fig-0008" title="">Analysis 1.5</a>; <a href="./references#CD008901-fig-0025" title="">Analysis 2.7</a>; <a href="./references#CD008901-fig-0026" title="">Analysis 2.8</a>; <a href="./references#CD008901-fig-0027" title="">Analysis 2.9</a>; <a href="./references#CD008901-fig-0049" title="">Analysis 3.4</a>; <a href="./references#CD008901-fig-0050" title="">Analysis 3.5</a>; <a href="./references#CD008901-fig-0064" title="">Analysis 4.4</a>; <a href="./references#CD008901-fig-0065" title="">Analysis 4.5</a>). Weight and LBM were reported as outcomes only in the comparison of rhGH versus no treatment, both of the outcomes showed statistically significant improvements in the rhGH group in trials that enrolled pre‐pubertal participants (<a href="./references#CD008901-fig-0029" title="">Analysis 2.11</a>; <a href="./references#CD008901-fig-0033" title="">Analysis 2.15</a>). Whilst the improvement in the anthropometric parameters is encouraging, this improvement is expected in the first year of rhGH administration. As none of the trials were longer than one year, it is not known whether this will continue with longer‐term administration of rhGH. There was no statistically significant change in QoL with rhGH therapy (<a href="./references#CD008901-fig-0034" title="">Analysis 2.16</a>). </p> <p>A statistically significant difference was seen in the measured insulin levels in the rhGH treated group compared to no treatment (<a href="./references#CD008901-fig-0035" title="">Analysis 2.17</a>). There was a significant difference in FBG levels between the groups in all comparisons (<a href="./references#CD008901-fig-0011" title="">Analysis 1.8</a>; <a href="./references#CD008901-fig-0036" title="">Analysis 2.18</a>; <a href="./references#CD008901-fig-0053" title="">Analysis 3.8</a>; <a href="./references#CD008901-fig-0068" title="">Analysis 4.8</a>), but this may not be clinically meaningful as none of the participants crossed the threshold for the diagnosis of diabetes. Other measures of blood glucose regulation such as PPBG levels (<a href="./references#CD008901-fig-0012" title="">Analysis 1.9</a>; <a href="./references#CD008901-fig-0037" title="">Analysis 2.19</a>; <a href="./references#CD008901-fig-0054" title="">Analysis 3.9</a>; <a href="./references#CD008901-fig-0069" title="">Analysis 4.9</a>), Hemoglobin A1c (<a href="./references#CD008901-fig-0038" title="">Analysis 2.20</a>), or the change from baseline in Hemoglobin A1c (<a href="./references#CD008901-fig-0039" title="">Analysis 2.21</a>) were similar across the two treatment groups. </p> <p>Exercise capacity was measured in three trials in different formats (measurements of exercise capacity, VO2 max or six‐minute walk test) and showed significant improvement in the rhGH‐treated participants compared to those receiving no treatment (<a href="./references#CD008901-fig-0040" title="">Analysis 2.22</a>; <a href="./references#CD008901-fig-0041" title="">Analysis 2.23</a>). However, there was unclear evidence from other comparisons of any beneficial treatment effect (<a href="./references#CD008901-fig-0013" title="">Analysis 1.10</a>; <a href="./references#CD008901-fig-0014" title="">Analysis 1.11</a>; <a href="./references#CD008901-fig-0042" title="">Analysis 2.24</a>; <a href="./references#CD008901-fig-0055" title="">Analysis 3.10</a>; <a href="./references#CD008901-fig-0056" title="">Analysis 3.11</a>; <a href="./references#CD008901-fig-0070" title="">Analysis 4.10</a>; <a href="./references#CD008901-fig-0071" title="">Analysis 4.11</a>). </p> <p>As expected, an increase was noted in the serum levels of IGF‐1 and IGFBP‐3 when rhGH was administered (<a href="./references#CD008901-fig-0015" title="">Analysis 1.12</a>; <a href="./references#CD008901-fig-0057" title="">Analysis 3.12</a>; <a href="./references#CD008901-fig-0058" title="">Analysis 3.13</a>; <a href="./references#CD008901-fig-0072" title="">Analysis 4.12</a>; <a href="./references#CD008901-fig-0073" title="">Analysis 4.13</a>). There was no significant difference in adverse effects of therapy in any of the comparisons (<a href="./references#CD008901-fig-0018" title="">Analysis 1.15</a>; <a href="./references#CD008901-fig-0045" title="">Analysis 2.27</a>; <a href="./references#CD008901-fig-0060" title="">Analysis 3.15</a>; <a href="./references#CD008901-fig-0075" title="">Analysis 4.15</a>). A statistically significant decrease in hospitalisations was reported in three trials at 12 months (<a href="./references#CD008901-fig-0044" title="">Analysis 2.26</a>). Pulmonary exacerbations were measured in one trial at six months and did not show a significant difference between standard dose or high‐dose of rhGH as compared to placebo (<a href="./references#CD008901-fig-0017" title="">Analysis 1.14</a>; <a href="./references#CD008901-fig-0059" title="">Analysis 3.14</a>; <a href="./references#CD008901-fig-0074" title="">Analysis 4.14</a>). It is possible that the benefit of therapy from rhGH requires a longer duration of therapy. No systematic assessment of cost‐effectiveness was performed by any trial, and there is unclear evidence on this measure at this time. </p> <p>No evidence of a difference in outcomes was found between the standard‐dose versus high‐dose in one under‐powered trial (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>), except for IGF‐1 (<a href="./references#CD008901-fig-0072" title="">Analysis 4.12</a>) and IGFBP3 levels (<a href="./references#CD008901-fig-0073" title="">Analysis 4.13</a>). </p> </section> <section id="CD008901-sec-0175"> <h3 class="title" id="CD008901-sec-0175">Overall completeness and applicability of evidence</h3> <p>The small number of participants in each of the trials limits the overall completeness and ultimately the generalisation of the evidence to the wider CF population. The majority of the trials excluded those with pre‐existing diabetes or those with impaired glucose intolerance. It is known that rhGH can cause disturbances in glucose metabolism and people with CF have a high incidence of CFRD which increases with age. The exclusion of these people introduced selection bias and limits the external validity of the evidence. </p> <p>In clinical practice, rhGH is given to pre‐pubertal adolescents for longer than one year. Therefore, the short duration and follow‐up of the included trials in this review does not allow complete assessment of the effects of the treatment in a clinical context. </p> </section> <section id="CD008901-sec-0176"> <h3 class="title" id="CD008901-sec-0176">Quality of the evidence</h3> <p>Overall, there was very low to low‐certainty of evidence to support the outcomes assessed in this review, primarily due to the small size of the trials and absence of the details that would allow assessment of risk of bias, such as sequence generation, allocation concealment and absence of blinding in the participants and absence of information on the blinding at the time of statistical analysis (<a href="./full#CD008901-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD008901-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD008901-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD008901-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD008901-sec-0177"> <h4 class="title">Limitations in trial design and implementation</h4> <p>The key factors that are likely to have had a degree of impact on the certainty of the evidence for the outcomes sought in this review can be linked to the design and implementation of the included trials, and in particular to the effective concealment of the allocation sequence and adequate blinding of investigators and outcome assessors. The absence of a placebo and blinding in most of the trials increases the risk of performance and detection bias. It was not possible to blind the control group due to the invasive nature of the treatment. The review captured objective outcomes such as pulmonary function tests, nutritional parameters, blood glucose changes, serum hormone levels and disease status. It is postulated that these outcomes have a low risk of bias despite the absence of a placebo or blinding. The impact of a lack of blinding cannot be ruled out on subjective outcomes such as QoL and exercise capacity. </p> <p>The duration of the endpoints in the trials included in this review was up to 12 months, which is not reflective of clinical practice. Administration of rhGH causes acceleration of growth in the first year of administration, but it is unclear whether this effect will be sustained. It is also not clear whether participants in the control group will achieve the same height and weight without therapy if followed up for a longer time period. </p> </section> <section id="CD008901-sec-0178"> <h4 class="title">Indirectness of the evidence</h4> <p>Although the participants in the included trials were a general representative sample as defined in the inclusion criteria, trials consistently excluded children with impaired glucose tolerance or pre‐existing diabetes. It is well known that the prevalence of diabetes in the CF population is larger than in the general population and by the age of 30, the prevalence rate has been estimated as 50% (<a href="./references#CD008901-bbs2-0058" title="O'RiordanSM , DattaniMT , HindmarshPC . Cystic fibrosis-related diabetes in childhood. Hormone Research in Paediatrics2010;73(1):15-24. [PMID: 20190536]">O'Riordan 2010</a>). Therefore, we have concerns that the findings here may not be indicative of the effects of the intervention on this population. For more details of the populations investigated and the directness of participants identified in the review (see '<a href="./references#CD008901-sec-0206" title="">Characteristics of included studies</a>'). </p> </section> <section id="CD008901-sec-0179"> <h4 class="title">Imprecision of results</h4> <p>The trials identified for inclusion in this systematic review considered only two doses of rhGH; across these trials, there were a number of outcomes that were measured and indeed able to be pooled. Heterogeneity occurred in a number of analyses, but this was likely to be due to the small number of included trials. In the data which we present, the precision of the estimates could be determined by the width of the CI surrounding it, relative to the distance from a null effect. There was a clear effect and little inconsistency for the following outcomes: height; weight; LBM; and IGF‐1 and IGFBP3 levels. There are hints of improvement in pulmonary function in the trials that measured these outcomes at 12 months. It is possible that the short duration of administration is not enough to capture the beneficial effects (if any) of rhGH therapy. Only a single trial was included in the first, third and fourth comparisons, so we advise caution when interpreting these results since they reflect few participants. </p> </section> <section id="CD008901-sec-0180"> <h4 class="title">Inconsistency of the results</h4> <p>The small number of trials that investigated the effect of rhGH compared to no treatment did permit some pooling of data. Therefore, any inferences about the inconsistency of the results could only be drawn from this comparison. Most of the meta‐analyses carried out for this comparison illustrated a low degree of unexplained heterogeneity and allowed us to conclude that the differences in treatment effect seen between the trials may not be important. In the instances where heterogeneity was considered to potentially impact on the findings, additional sensitivity analyses were carried out as described in Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008901-bbs2-0039" title="DeeksJJ , HigginsJP , Altman DG on behalf of the CSMG , editor(s). Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Deeks 2011</a>), where the overall treatment benefit would be concluded on the basis of both the original and subsequent sensitivity analysis findings. </p> </section> <section id="CD008901-sec-0181"> <h4 class="title">Publication bias</h4> <p>Although all effort was made to search for unpublished data, it is possible that unpublished trials with unfavourable results may not have been identified in the search, which could potentially alter the results of the review. Three of the included trials were funded in part by industry‐sponsored grants. We were unable to contact the authors of the trials to understand the process of funding and whether industry support was limited to the supply of the medication or extended to statistical and analysis support. We were also unable to contact authors of unpublished trials listed in the database http://clinical trials.gov. </p> <p>In view of the low number of trials included in this review an assessment of publication bias was not possible. </p> </section> </section> <section id="CD008901-sec-0182"> <h3 class="title" id="CD008901-sec-0182">Potential biases in the review process</h3> <p>We made every attempt to limit bias in the review process by ensuring a comprehensive search for potentially eligible trials. The authors’ independent assessments of eligibility of trials for inclusion in this review and the extraction of data minimized the potential for additional bias beyond that detailed in the '<a href="#CD008901-sec-0049">Risk of bias in included studies</a>' tables. The incompleteness of some of the reports and our inability to obtain clarification of certain trial details or to resolve ambiguities in the reports may have contributed to some bias in their assessment, but where these conditions applied, this was explicitly stated in the text of our review. The effects of language bias on the identification and selection of studies for inclusion in a systematic review is widely recognised and therefore we ensured that any trials that were not in the English language were translated so that they could be assessed for eligibility. </p> </section> <section id="CD008901-sec-0183"> <h3 class="title" id="CD008901-sec-0183">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review on the use of rhGh in people with CF was commissioned by the Agency for Health Care Research and Quality (AHRQ), United States of America (<a href="./references#CD008901-bbs2-0059" title="PhungOJ , ColemanCI , BakerEL , ScholleJM , GirottoJE , MakanjiSS , et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics2010;126(5):e1211-26. [PMID: 20921071]">Phung 2010</a>). The searches undertaken were without language or publication status restrictions. The review design followed the standard PRISMA protocol and used a standardised data extraction form completed independently by two review authors. However, the details of the format and risk of bias analysis of the included trials are not available for review. All the trials included in the Phung review were graded as 'low risk of bias' although details of randomisation, allocation concealment, blinding of participants and outcome assessors are not available for most of the included trials. For our review, the search strategy was wider in including Web of Science and Scopus and online trials registries to identify ongoing trials. We have presented detailed information on the trials in the risk of bias analysis which makes the assessment of the outcome results more robust. </p> <p>In the Phung review, 10 controlled trials and eight observational studies were included. The results of retrospective and observational studies, whilst providing valuable information on a range of clinical variables, do not constitute reliable high‐level evidence for the effects of the interventions considered in this review. In addition to the controlled trials we have included in our review, Phung included one trial which was retrospective (<a href="./references#CD008901-bbs2-0016" title="HardinDS , FerkolT , AhnC , DreimaneD , DysonM , MorseM , et al. A retrospective study of growth hormone use in adolescents with cystic fibrosis. Clinical Endocrinology2005;62(5):560-6. [PMID: 15853825]">Hardin 2005c</a>) and another which used glutamine in addition to rhGH (<a href="./references#CD008901-bbs2-0011" title="DarmaunD , HayesV , SchaefferD , WelchS , MaurasN . Effects of glutamine and recombinant human growth hormone on protein metabolism in prepubertal children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2004;89(3):1146-52. [CFGD REGISTER: GN90b] SchaefferD , DarmaunD , PunatiJ , MaurasN , HayesVY . Use of glutamine and recombinant human growth hormone (RHGH) in children with cystic fibrosis [abstract]. Pediatric Pulmonology2000;30 (Suppl 20):323. [CFGD REGISTER: GN90a] ">Darmaun 2004</a>). We disagree with the inclusion of these two trials and pooling of data in the analysis. It is to be noted that participants in the Darmaun trial received intravenous glutamine prior to receiving rhGH for a duration of four weeks (<a href="./references#CD008901-bbs2-0011" title="DarmaunD , HayesV , SchaefferD , WelchS , MaurasN . Effects of glutamine and recombinant human growth hormone on protein metabolism in prepubertal children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2004;89(3):1146-52. [CFGD REGISTER: GN90b] SchaefferD , DarmaunD , PunatiJ , MaurasN , HayesVY . Use of glutamine and recombinant human growth hormone (RHGH) in children with cystic fibrosis [abstract]. Pediatric Pulmonology2000;30 (Suppl 20):323. [CFGD REGISTER: GN90a] ">Darmaun 2004</a>). The inclusion of these data with the other trials in a meta‐analysis is not appropriate due to the varying duration of treatment. Additionally, combining data reported at six months and 12 months is not appropriate. We identified substantial heterogeneity when such an analysis was attempted and have chosen to present the data for six months and 12 months in different subgroups. The quality of nine out of 10 controlled trials included in the AHRQ review was assessed as "fair" based on the validity assessment of the EPC guide. There are no details of the assessment of the individual trials in that review based on the criteria of the EPC guidelines; unlike the assessment of those trials included in this review (<a href="#CD008901-fig-0003">Figure 3</a>). We agree with the assessment of the trials that appear in both reviews. One trial was assessed by both the reviews to be of high quality (<a href="./references#CD008901-bbs2-0007" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;31(4):815-21. [CFGD REGISTER: GN127e] GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-Arginine and nitrate concentrations in serum but decreased exhaled oxide in patients with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):335. [CFGD REGISTER: GN127b] GrasemannH , GrasemannC , SchnabelD , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis [abstract]. In: Proceedings of the American Thoracic Society International Conference; 2006 May 19-24; California, USA. 2006:A408. [CFGD REGISTER: GN127a] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics2007;119(6):e1230-8. [CFGD REGISTER: GN127d] SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 (Suppl 29):393. [CFGD REGISTER: GN127c] ">Schnabel 2007</a>), whilst all others were assessed as fair. </p> <p>However, despite the differences in the conduct of the two reviews, the results were similar. It is acknowledged that the role of rhGH in the care of people with CF is unclear at this point. Phung reported improvements in height, weight and bone mineral capacity and some improvements in pulmonary functions (<a href="./references#CD008901-bbs2-0059" title="PhungOJ , ColemanCI , BakerEL , ScholleJM , GirottoJE , MakanjiSS , et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics2010;126(5):e1211-26. [PMID: 20921071]">Phung 2010</a>). We have also found improvements in anthropometric data at 12 months and hints of change in FEV<sub>1</sub> and FVC when compared to baseline levels. We would like to emphasize that the only improvement noticed in both the reviews in pulmonary function is small and the generalisation of this result as "rhGH improved almost all intermediate results of pulmonary functions, height and weight in patients with CF" may be misleading (<a href="./references#CD008901-bbs2-0059" title="PhungOJ , ColemanCI , BakerEL , ScholleJM , GirottoJE , MakanjiSS , et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics2010;126(5):e1211-26. [PMID: 20921071]">Phung 2010</a>). The lack of information on the effects of rhGH on blood glucose (FBG, PPBG and random blood glucose levels), haemoglobin A1c, IGF‐1 and IGFBP3 as well as long‐term side effects are acknowledged. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008901-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008901-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008901-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008901-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 1: FEV1 (% predicted) change from baseline" data-id="CD008901-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 1: FEV<sub>1</sub> (% predicted) change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 2: FEV1 (Z‐score) change from baseline" data-id="CD008901-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 2: FEV<sub>1</sub> (Z‐score) change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 3: FVC (% predicted) change from baseline" data-id="CD008901-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 3: FVC (% predicted) change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 4: Height (z score)" data-id="CD008901-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 4: Height (z score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 5: Height velocity (cm/year)" data-id="CD008901-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 5: Height velocity (cm/year)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 6: Weight change from baseline (kg)" data-id="CD008901-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 6: Weight change from baseline (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 7: Lean body mass (kg) ‐ change from baseline" data-id="CD008901-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 7: Lean body mass (kg) ‐ change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 8: Fasting blood glucose (mg/dL)" data-id="CD008901-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 8: Fasting blood glucose (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 9: Postprandial blood glucose (mg/dL)" data-id="CD008901-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 9: Postprandial blood glucose (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 10: Exercise capacity (watts)" data-id="CD008901-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 10: Exercise capacity (watts)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 11: VO2 max (mL/min)" data-id="CD008901-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 11: VO2 max (mL/min)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 12: Insulin like growth factor (IGF‐1) (Z‐score)" data-id="CD008901-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 12: Insulin like growth factor (IGF‐1) (Z‐score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 13: IGFBP‐3 (z score)" data-id="CD008901-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 13: IGFBP‐3 (z score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 14: Number of pulmonary exacerbations" data-id="CD008901-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 14: Number of pulmonary exacerbations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Standard rhGH versus placebo, Outcome 15: Adverse effects" data-id="CD008901-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Standard rhGH versus placebo, Outcome 15: Adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 1: FEV1 (% predicted)" data-id="CD008901-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 1: FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 2: FEV1 change from baseline" data-id="CD008901-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 2: FEV<sub>1</sub> change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 3: FVC (% predicted)" data-id="CD008901-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 3: FVC (% predicted)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 4: FVC change from baseline" data-id="CD008901-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 4: FVC change from baseline</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 5: Peak inspiratory pressure (PIP), mm Hg" data-id="CD008901-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 5: Peak inspiratory pressure (PIP), mm Hg </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 6: Peak expiratory pressure (mm Hg)" data-id="CD008901-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 6: Peak expiratory pressure (mm Hg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 7: Height (z score)" data-id="CD008901-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 7: Height (z score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 8: Height (cm) change from baseline" data-id="CD008901-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 8: Height (cm) change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 9: Height velocity (cm/year)" data-id="CD008901-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 9: Height velocity (cm/year)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 10: Height percentile rank" data-id="CD008901-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 10: Height percentile rank</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 11: Weight (z score)" data-id="CD008901-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 11: Weight (z score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 12: Weight (kg) change from baseline" data-id="CD008901-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 12: Weight (kg) change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 13: Weight velocity (kg/year)" data-id="CD008901-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 13: Weight velocity (kg/year)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 14: Weight percentile rank" data-id="CD008901-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 14: Weight percentile rank</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 15: Lean body mass change (kg)" data-id="CD008901-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 15: Lean body mass change (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 16: Quality of life" data-id="CD008901-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 16: Quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 17: Plasma insulin level (μU/mL)" data-id="CD008901-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 17: Plasma insulin level (μU/mL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 18: Fasting blood glucose (mg/dL)" data-id="CD008901-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 18: Fasting blood glucose (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 19: Postprandial blood glucose (mg/dL)" data-id="CD008901-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 19: Postprandial blood glucose (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 20: Hemoglobin A1c (%)" data-id="CD008901-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 20: Hemoglobin A1c (%)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 21: Change in haemoglobin A1c from baseline (%)" data-id="CD008901-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 21: Change in haemoglobin A1c from baseline (%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 22: Exercise capacity (watts)" data-id="CD008901-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 22: Exercise capacity (watts)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 23: VO2 max" data-id="CD008901-fig-0041" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 23: VO2 max</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 24: Six‐minute walk test (m) change from baseline" data-id="CD008901-fig-0042" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 24: Six‐minute walk test (m) change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 25: IGF‐1 level (ng/dL)" data-id="CD008901-fig-0043" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 25: IGF‐1 level (ng/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 26: Hospitalisation" data-id="CD008901-fig-0044" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 26: Hospitalisation</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-002.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Standard rhGH versus no treatment, Outcome 27: Adverse events" data-id="CD008901-fig-0045" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-002.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2: Standard rhGH versus no treatment, Outcome 27: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-002.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 1: FEV1 (% predicted)" data-id="CD008901-fig-0046" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 1: FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 2: FEV1 (z score) change from baseline" data-id="CD008901-fig-0047" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 2: FEV<sub>1</sub> (z score) change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 3: FVC (% predicted)" data-id="CD008901-fig-0048" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 3: FVC (% predicted)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 4: Height velocity (z score)" data-id="CD008901-fig-0049" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 4: Height velocity (z score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 5: Height velocity (cm/year)" data-id="CD008901-fig-0050" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 5: Height velocity (cm/year)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 6: Weight (kg) change from baseline" data-id="CD008901-fig-0051" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 6: Weight (kg) change from baseline</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 7: Lean body mass (kg)" data-id="CD008901-fig-0052" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 7: Lean body mass (kg)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 8: Fasting blood glucose (mg/dL)" data-id="CD008901-fig-0053" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 8: Fasting blood glucose (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 9: Postprandial blood glucose (mg/dL)" data-id="CD008901-fig-0054" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 9: Postprandial blood glucose (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 10: Exercise capacity (watts)" data-id="CD008901-fig-0055" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 10: Exercise capacity (watts)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 11: VO2 max (mL/min)" data-id="CD008901-fig-0056" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 11: VO2 max (mL/min)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 12: IGF‐1 (z score)" data-id="CD008901-fig-0057" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 12: IGF‐1 (z score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 13: IGFBP‐3 (z score)" data-id="CD008901-fig-0058" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 13: IGFBP‐3 (z score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 14: Number of pulmonary exacerbations" data-id="CD008901-fig-0059" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 14: Number of pulmonary exacerbations</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: High‐dose rhGH versus placebo, Outcome 15: Adverse effects" data-id="CD008901-fig-0060" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: High‐dose rhGH versus placebo, Outcome 15: Adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 1: FEV1 (% predicted)" data-id="CD008901-fig-0061" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 1: FEV<sub>1</sub> (% predicted) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 2: FEV1 (z score) change from baseline" data-id="CD008901-fig-0062" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 2: FEV<sub>1</sub> (z score) change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 3: FVC (% predicted)" data-id="CD008901-fig-0063" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 3: FVC (% predicted)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 4: Height velocity (z score)" data-id="CD008901-fig-0064" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 4: Height velocity (z score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 5: Height velocity (cm/year)" data-id="CD008901-fig-0065" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 5: Height velocity (cm/year) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 6: Weight (kg) change from baseline" data-id="CD008901-fig-0066" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 6: Weight (kg) change from baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 7: Lean body mass (kg)" data-id="CD008901-fig-0067" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 7: Lean body mass (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 8: Fasting blood glucose (mg/dL)" data-id="CD008901-fig-0068" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 8: Fasting blood glucose (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 9: Post‐prandial blood glucose (mg/dL)" data-id="CD008901-fig-0069" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 9: Post‐prandial blood glucose (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 10: Exercise capacity (watts)" data-id="CD008901-fig-0070" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 10: Exercise capacity (watts) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 11: VO2 max (mL/min)" data-id="CD008901-fig-0071" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 11: VO2 max (mL/min)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 12: IGF‐1 (z score)" data-id="CD008901-fig-0072" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 12: IGF‐1 (z score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 13: IGFBP‐3 (z score)" data-id="CD008901-fig-0073" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 13: IGFBP‐3 (z score)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 14: Number of pulmonary exacerbations" data-id="CD008901-fig-0074" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 14: Number of pulmonary exacerbations </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008901-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/urn:x-wiley:14651858:media:CD008901:CD008901-CMP-004.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 15: Adverse effects" data-id="CD008901-fig-0075" src="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_t/tCD008901-CMP-004.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4: High‐dose rhGH versus standard dose rhGH, Outcome 15: Adverse effects</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/media/CDSR/CD008901/image_n/nCD008901-CMP-004.15.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008901-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Standard rhGH compared to placebo for cystic fibrosis in children and young adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard rhGH compared with placebo for children and young adults with CF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and young adults with CF </p> <p><b>Settings</b>: outpatient </p> <p><b>Intervention</b>: standard rhGH </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard rhGH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> <p>change since baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change in FEV<sub>1</sub> % predicted since baseline in the control group was 1% (23%). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the standard rhGH group was <b>2.50% higher</b> (8.60 lower to 13.60 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences were found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC (% predicted)</b> </p> <p>change since baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change in FVC % predicted from baseline in the control group was ‐0.70% (15.1%). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC (% predicted) in the standard rhGH group was <b>3.80% higher</b><br/>(4.67 lower to 12.27 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences were found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Height velocity (cm/year)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) height velocity in the control group was 3.5 (2.3) cm/year.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean height velocity in the standard rhGH group was <b>2.1 cm/year higher</b> (0.54 lower to 3.66 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Height velocity (change in height measured in cm/year) showed significant improvement in those receiving standard rhGH; however, there was no statistically significant difference in the height z score between treatment groups. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight (kg)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in weight in the control group was 1.4 (1.7) kg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight in the standard rhGH group was <b>1.00 kg higher</b> (‐0.08 lower to 2.08 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant differences were found between the two treatment groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schnabel used standardised CF HRQoL questionnaires and reported no major differences among the treatment groups (no data available for analysis). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fasting blood glucose (mg/dL)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) fasting blood glucose level in the control group was 88.8 (13.7) mg/dL.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fasting blood glucose level in the standard rhGH group was <b>12.40 mg/dL higher</b> (3.76 higher to 21.04 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference found in favour of the standard rhGH group.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of pulmonary exacerbations or hospitalisations</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 pulmonary exacerbations per 1000 participants.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 pulmonary exacerbations per 1000 participants (89 to 835).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.50<br/>(0.49 to 4.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR greater than 1 indicates an advantage for placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) in the standard rhGH group is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CF</b> : cystic fibrosis;<b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume at one second; <b>FVC:</b> forced vital capacity; <b>HRQoL</b> : health‐related quality of life; <b>N/A</b> : not applicable; <b>QoL</b> : quality of life; <b>rhGH</b> : recombinant growth hormone; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to unclear risk of bias due to lack of detail on generation of allocation sequence, allocation concealment, incomplete outcome data and support from a pharmaceutical company. </p> <p>2. Downgraded due to small sample size and wide CIs.</p> <p>3. Downgraded due to lack of data for analysis.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Standard rhGH compared to placebo for cystic fibrosis in children and young adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008901-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Standard rhGH compared to no treatment for cystic fibrosis in children and young adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Standard rhGH compared with no treatment for children and young adults with CF</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and young adults with CF </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> standard rhGH </p> <p><b>Comparison:</b> no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>No treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard rhGH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub>(% predicted)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the control group was ‐0.4 (4.1). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted) in the intervention group was <b>0.29 higher</b> (0.62 lower to 1.19 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference between treatment groups. The change in FEV<sub>1</sub>`(L) was reported by 2 trials (n = 75) and showed a significantly greater increase in the standard rhGH group, SMD 0.74 (95% CI 0.26 to 1.22). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>FVC (% predicted)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change in FVC % predicted in the control group was 0.4 (2.5) (‐0.1 to 0.4). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FVC % predicted in the intervention group was <b>1.00 higher</b> (0.03 higher to 1.96 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference found in favour of the standard rhGH group.</p> <p>The change in FVC (L) was reported by 2 trials (n = 75) and showed a significantly greater increase in the standard rhGH group, SMD 1.61 (95% CI 0.17 to 3.06). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Height velocity (cm/year)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (range) height velocity in the control group was 4.47 (3.71 to 5.3) cm/year.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean height in the intervention group was <b>3.53 cm/year higher</b> (2.77 higher to 4.30 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156 participants</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference found in favour of the standard rhGH group.</p> <p>There was a similar result in favour of the rhGH treatment group in height z score measured at the end of the trial, MD 0.58 (95% CI 0.36 to 0.80). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight (kg)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (range) change in weight from baseline in the control group was 1.75 kg (0.7 to 2.8). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight in the intervention group was <b>1.00 kg higher</b> (0.32 lower to 1.68 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 participants</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A separate study found no statistically significant difference between the two groups in change from baseline (kg) at six months. </p> <p>In relation to weight velocity, results were consistently significantly higher in the rhGH group at 12 months. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Change from baseline</p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in HRQoL score in the control group was 0.3 (0.8).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in HRQoL score in the intervention group was <b>0.10 higher</b> (0.32 lower to 0.52 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups; however, the same trial reported a significant difference in Body Image Score favouring rhGH. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fasting blood glucose (mg/dL)</b> </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (range) fasting blood glucose in the control group was 93.33 mg/dL (88.90 mg/dL to 101.00 mg/dL). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fasting blood glucose in the intervention group was <b>3.2 mg/dL higher</b> (6.09 mg/dL lower to 12.49 mg/dL higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 participants</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between the two groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of pulmonary exacerbations or hospitalisations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (range) number of hospitalisations in the control group was 2.70 (2.2 to 3.0). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of hospitalisations in the intervention group was <b>1.34 lower</b> (1.75 lower to 0.93 lower). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94 participants</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference found in favour of the standard rhGH group.</p> <p>The episodes of hospitalisations were reported as mean and SD between the 2 groups in these studies. The total number of hospitalisations in each group are not available to calculate RR. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CF</b> : cystic fibrosis;<b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume at 1 second; <b>FVC:</b> forced vital capacity; <b>HRQoL</b> : health‐related quality of life; <b>N/A</b> : not applicable; <b>QoL</b> : quality of life; <b>rhGH</b> : recombinant growth hormone; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to unclear risk of bias for generation of allocation sequence, allocation concealment and selective reporting </p> <p>2. Downgraded due to high risk of bias for blinding or incomplete outcome data or support from a pharmaceutical company (or combination of these) . </p> <p>3. Downgraded due to small sample size and wide CIs.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Standard rhGH compared to no treatment for cystic fibrosis in children and young adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008901-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High‐dose rhGH compared to placebo for children and young adults with cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High‐dose rhGH compared to placebo for children and young adults with CF</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : children and young adults with CF<br/><b>Setting</b> : outpatient<br/><b>Intervention</b> : high‐dose rhGH<br/><b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>High‐dose rhGH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in FEV<sub>1</sub> % predicted in the control group was 1.0 (23.0)% predicted. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in FEV<sub>1</sub> % predicted in the intervention group was <b>3.30% higher</b> (8.16% lower to 14.76% higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC (% predicted)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in FVC % predicted in the control group was ‐0.70 (15.10) % predicted. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in FVC % predicted in the intervention group was <b>6.70% higher</b> (1.41% lower to 14.81% higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Height velocity (cm/year)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) height velocity in the control group was 3.5 (2.3) cm/year.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean height velocity in the intervention group was <b>3.30 cm/year higher</b> (1.17 higher to 5.43 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Statistically significant difference found in favour of the standard rhGH group.</p> <p>A similarly significant result was also seen in the height z score at the end of the study. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight (kg)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change in weight from baseline in the control group was 1.4 (1.7) kg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight in the intervention group was <b>0.80 kg higher</b> (0.44 lower to 2.04 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>QoL</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>very</b> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schnabel reported QoL using standardised CF HRQoL questionnaires, but did not provide data we could enter into the analysis; the published paper reported no major differences between the treatment groups. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fasting blood glucose (mg/dL)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) fasting blood glucose in the control group was 88.8 (13.7) mg/dL.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fasting blood glucose in the intervention group was <b>8.00 mg/dL higher</b> (0.30 mg/dL lower to 16.3 mg/dL higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of pulmonary exacerbations or hospitalisations</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 pulmonary exacerbations per 1,000 participants.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 pulmonary exacerbations per 1,000 participants (120 to 1021).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.92 (0.66 to 5.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR over 1 indicates an advantage for placebo.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CF</b> : cystic fibrosis; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume at 1 second; <b>FVC:</b> forced vital capacity; <b>HRQoL</b> : health‐related quality of life; <b>N/A</b> : not applicable; <b>QoL</b> : quality of life; <b>rhGH</b> : recombinant growth hormone; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to unclear risk of bias due to lack of detail on generation of allocation sequence, allocation concealment, incomplete outcome data and support from a pharmaceutical company. </p> <p>2. Downgraded due to small sample size and wide CIs.</p> <p>3. Downgraded due to lack of data for analysis.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High‐dose rhGH compared to placebo for children and young adults with cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008901-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">High‐dose rhGH compared to standard‐dose rhGH for children and young adults with cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High‐dose rhGH compared to standard dose rhGH for children and young adults with CF</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and young adults with CF<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> high‐dose rhGH<br/><b>Comparison:</b> standard‐dose rhGH </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Standard‐dose rhGH</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>High‐dose rhGH</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> (% predicted)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) absolute change from baseline in FEV<sub>1</sub> % predicted in the standard‐dose group was 5.60 (2.90)% predicted. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean absolute change from baseline in FEV<sub>1</sub> % predicted in the high‐dose group was <b>1.20% higher</b> (1.04% lower to 3.44% higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups. This was also true for FEV<sub>1</sub> z score. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC (% predicted)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) absolute change from baseline in FVC % predicted in the standard‐dose group was ‐0.70 (15.1) % predicted. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean absolute change from baseline in FVC % predicted in the high‐dose group was <b>6.70% higher</b> (1.29% lower to 14.69% higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Height velocity (cm/year)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in height velocity in the standard‐dose group was 5.6 (2.9) cm/year. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in height velocity in the high‐dose group was <b>1.20 cm/year higher</b> (1.04 lower to 3.44 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups. Also no difference between groups in height velocity z score. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight (kg)</b> </p> <p>Change from baseline</p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) change from baseline in weight in the standard‐dose group was 2.4 (1.9) kg. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in weight in the high‐dose group was <b>0.2 kg lower</b> (1.48 kg lower to 1.08 kg higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fasting blood glucose (mg/dL)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean (SD) fasting blood glucose level in the standard‐dose group was 101.20 (15.2) mg/dL. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean fasting blood glucose level in the high‐dose group was <b>4.40 mg/dL lower</b> (13.05 mg/dL lower to 4.25 mg/dL higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No statistically significant difference found between treatment groups.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of pulmonary exacerbations or hospitalisations</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 pulmonary exacerbations per 1000 participants.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>350 pulmonary exacerbations per 1000 participants (142 to 868).</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.28<br/>(0.52 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 participants<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR greater than 1 indicates an advantage for standard rhGH.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CF</b> : cystic fibrosis; <b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume at 1 second; <b>FVC:</b> forced vital capacity; <b>HRQoL</b> : health‐related quality of life; <b>N/A</b> : not applicable; <b>QoL</b> : quality of life; <b>rhGH</b> : recombinant growth hormone; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Downgraded due to unclear risk of bias for generation of allocation sequence, concealment of allocation, lack of blinding of outcome assessment, incomplete outcome data and support from a pharmaceutical company. </p> <p>2. Downgraded due to small sample size.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">High‐dose rhGH compared to standard‐dose rhGH for children and young adults with cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/full#CD008901-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008901-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Standard rhGH versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 FEV<sub>1</sub> (% predicted) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [‐8.60, 13.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 FEV<sub>1</sub> (Z‐score) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.23, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 FVC (% predicted) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [‐4.67, 12.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Height (z score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [‐0.77, 5.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Height velocity (cm/year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.54, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Weight change from baseline (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐0.08, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Lean body mass (kg) ‐ change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐0.40, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Fasting blood glucose (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.40 [3.76, 21.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Postprandial blood glucose (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.10 [‐7.18, 31.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Exercise capacity (watts) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.80 [‐0.90, 20.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 VO2 max (mL/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.10 [‐3.85, 24.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Insulin like growth factor (IGF‐1) (Z‐score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.68, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 IGFBP‐3 (z score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [‐0.10, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Number of pulmonary exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.49, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Any adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.67, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Severe adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.39, 4.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Standard rhGH versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008901-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Standard rhGH versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 FEV<sub>1</sub> (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.65, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 FEV<sub>1</sub> change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐1.06, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.21, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 FVC (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [‐9.50, 15.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 FVC change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [‐0.48, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.55, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Peak inspiratory pressure (PIP), mm Hg <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.00 [‐28.69, ‐13.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Peak expiratory pressure (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.00 [16.89, 29.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Height (z score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.36, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Height (cm) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [‐0.07, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Height velocity (cm/year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.51 [2.21, 6.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [2.77, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Height percentile rank <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.20 [10.84, 13.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Weight (z score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.21, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [‐0.07, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Weight (kg) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐0.22, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.18, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Weight velocity (kg/year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [1.27, 4.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [1.53, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Weight percentile rank <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.50 [4.02, 6.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Lean body mass change (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [2.01, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 At 12 months (age population pre‐puberty at entry of study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.13, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.3 At 12 months (age populations spans pubertal age range)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [1.85, 3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 Health Care Quality of Life (HRQOL) score change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.32, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.2 Body Image Score change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.03, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Plasma insulin level (μU/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.10 [2.40, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [‐0.60, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Fasting blood glucose (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [‐12.57, 20.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.20 [‐6.09, 12.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Postprandial blood glucose (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.00 [‐2.20, 12.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.75 [‐32.74, 11.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Hemoglobin A1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.44, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.66, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Change in haemoglobin A1c from baseline (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.30, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Exercise capacity (watts) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.10 [15.58, 30.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>31.90 [22.68, 41.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.23 VO2 max <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.1 At 6 months (mL/min)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.65 [0.60, 6.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.2 At 12 months (mL/kg/min)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [4.29, 7.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.24 Six‐minute walk test (m) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.90 [‐43.57, 95.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.25 IGF‐1 level (ng/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>152.00 [62.89, 241.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>198.17 [135.59, 260.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.26 Hospitalisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.26.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.34 [‐1.75, ‐0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.27 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.1 Drug‐related adverse effect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.73 [1.14, 307.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.2 Injection‐site bruising</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.38 [0.79, 225.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.3 Hyperglycaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.22, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.4 Papilledema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.11, 63.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.5 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.11, 63.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.6 Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.68 [0.11, 63.45]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Standard rhGH versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008901-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">High‐dose rhGH versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 FEV<sub>1</sub> (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [‐8.16, 14.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 FEV<sub>1</sub> (z score) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.24, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 FVC (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.70 [‐1.41, 14.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Height velocity (z score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [0.30, 6.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Height velocity (cm/year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [1.17, 5.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Weight (kg) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐0.44, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Lean body mass (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐0.67, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Fasting blood glucose (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.00 [‐0.30, 16.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Postprandial blood glucose (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.60 [‐23.32, 32.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Exercise capacity (watts) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.40 [‐13.20, 22.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 VO2 max (mL/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.00 [‐10.61, 58.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 IGF‐1 (z score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.18, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 IGFBP‐3 (z score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.11, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Number of pulmonary exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.66, 5.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 Any adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.62, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.2 Severe adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.32, 3.83]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">High‐dose rhGH versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008901-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">High‐dose rhGH versus standard dose rhGH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 FEV<sub>1</sub> (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐1.04, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 FEV<sub>1</sub> (z score) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.20, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 FVC (% predicted) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.70 [‐1.29, 14.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Height velocity (z score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [‐0.51, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Height velocity (cm/year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐1.04, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Weight (kg) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.48, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Lean body mass (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.69, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Fasting blood glucose (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.40 [‐13.05, 4.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Post‐prandial blood glucose (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.50 [‐38.36, 23.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Exercise capacity (watts) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.40 [‐22.96, 12.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 VO2 max (mL/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.90 [‐21.97, 49.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 IGF‐1 (z score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.18, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.13 IGFBP‐3 (z score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.11, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.14 Number of pulmonary exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.52, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.15 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.1 Any adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.58, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.2 Severe adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.27, 2.83]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">High‐dose rhGH versus standard dose rhGH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008901.pub5/references#CD008901-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008901.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008901-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008901-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008901-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008901-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD008901-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008901-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008901-note-0014">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD008901-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008901-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008901\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008901\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008901\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008901\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008901\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008901.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008901.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008901.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008901.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008901.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714068070"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008901.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714068074"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008901.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d65a5ab8c937d',t:'MTc0MDcxNDA2OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 